<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotic regimens for late‐onset neonatal sepsis - Korang, SK - 2021 | Cochrane Library</title> <meta content="Antibiotic regimens for late‐onset neonatal sepsis - Korang, SK - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013836.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotic regimens for late‐onset neonatal sepsis - Korang, SK - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013836.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013836.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotic regimens for late‐onset neonatal sepsis" name="citation_title"/> <meta content="Steven Kwasi Korang" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="kwasikorang@hotmail.com" name="citation_author_email"/> <meta content="Sanam Safi" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Chiara Nava" name="citation_author"/> <meta content='Ospedale "A. Manzoni"' name="citation_author_institution"/> <meta content="Gorm Greisen" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Munish Gupta" name="citation_author"/> <meta content="Beth Israel Deaconess Medical Center" name="citation_author_institution"/> <meta content="Ulrik Lausten-Thomsen" name="citation_author"/> <meta content="Paris South University Hospitals Le Kremlin-Bicêtre" name="citation_author_institution"/> <meta content="Janus C Jakobsen" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD013836.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/05/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013836.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013836.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013836.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amikacin [adverse effects, therapeutic use]; Ampicillin [adverse effects, therapeutic use]; Anti-Bacterial Agents [adverse effects, *therapeutic use]; Aztreonam [adverse effects, therapeutic use]; Bias; Cefazolin [adverse effects, therapeutic use]; Clavulanic Acid [adverse effects, therapeutic use]; Drug Therapy, Combination; Floxacillin [adverse effects, therapeutic use]; Gentamicins [adverse effects, therapeutic use]; Neonatal Sepsis [*drug therapy]; Randomized Controlled Trials as Topic; Ticarcillin [adverse effects, therapeutic use]; Vancomycin [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013836.pub2&amp;doi=10.1002/14651858.CD013836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="KUoIaN9D";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013836\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013836\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013836.pub2",title:"Antibiotic regimens for late\\u2010onset neonatal sepsis",firstPublishedDate:"May 8, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013836.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013836.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013836.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013836.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013836.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013836.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013836.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013836.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013836.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013836.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5935 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013836.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-sec-0130"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-sec-0019"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-sec-0020"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-sec-0048"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-sec-0120"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/appendices#CD013836-sec-0135"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/table_n/CD013836StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/table_n/CD013836StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotic regimens for late‐onset neonatal sepsis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information#CD013836-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Steven Kwasi Korang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information#CD013836-cr-0005">Sanam Safi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information#CD013836-cr-0006">Chiara Nava</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information#CD013836-cr-0007">Gorm Greisen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information#CD013836-cr-0008">Munish Gupta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information#CD013836-cr-0009">Ulrik Lausten-Thomsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information#CD013836-cr-0010">Janus C Jakobsen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information/en#CD013836-sec-0154">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 May 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013836.pub2">https://doi.org/10.1002/14651858.CD013836.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013836-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013836-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013836-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013836-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013836-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013836-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013836-abs-0001" lang="en"> <section id="CD013836-sec-0001"> <h3 class="title" id="CD013836-sec-0001">Background</h3> <p>Neonatal sepsis is a major cause of morbidity and mortality. It is the third leading cause of neonatal mortality globally constituting 13% of overall neonatal mortality<i>.</i> Despite the high burden of neonatal sepsis, high‐quality evidence in diagnosis and treatment is scarce. Due to the diagnostic challenges of sepsis and the relative immunosuppression of the newborn, many neonates receive antibiotics for suspected sepsis. Antibiotics have become the most used therapeutics in neonatal intensive care units, and observational studies in high‐income countries suggest that 83% to 94% of newborns treated with antibiotics for suspected sepsis have negative blood cultures. The last Cochrane Review was updated in 2005. There is a need for an updated systematic review assessing the effects of different antibiotic regimens for late‐onset neonatal sepsis. </p> </section> <section id="CD013836-sec-0002"> <h3 class="title" id="CD013836-sec-0002">Objectives</h3> <p>To assess the beneficial and harmful effects of different antibiotic regimens for late‐onset neonatal sepsis. </p> </section> <section id="CD013836-sec-0003"> <h3 class="title" id="CD013836-sec-0003">Search methods</h3> <p>We searched the following electronic databases: CENTRAL (2021, Issue 3); Ovid MEDLINE; Embase Ovid; CINAHL; LILACS; Science Citation Index EXPANDED and Conference Proceedings Citation Index – Science on 12 March 2021. We also searched clinical trials databases and the reference lists of retrieved articles for randomised controlled trials (RCTs) and quasi‐RCTs. </p> </section> <section id="CD013836-sec-0004"> <h3 class="title" id="CD013836-sec-0004">Selection criteria</h3> <p>We included RCTs comparing different antibiotic regimens for late‐onset neonatal sepsis. We included participants older than 72 hours of life at randomisation, suspected or diagnosed with neonatal sepsis, meningitis, osteomyelitis, endocarditis, or necrotising enterocolitis. We excluded trials that assessed treatment of fungal infections. </p> </section> <section id="CD013836-sec-0005"> <h3 class="title" id="CD013836-sec-0005">Data collection and analysis</h3> <p>Three review authors independently assessed studies for inclusion, extracted data, and assessed risk of bias. We used the GRADE approach to assess the certainty of evidence. Our primary outcome was all‐cause mortality, and our secondary outcomes were: serious adverse events, respiratory support, circulatory support, nephrotoxicity, neurological developmental impairment, necrotising enterocolitis, and ototoxicity. Our primary time point of interest was at maximum follow‐up. </p> </section> <section id="CD013836-sec-0006"> <h3 class="title" id="CD013836-sec-0006">Main results</h3> <p>We included five RCTs (580 participants). All trials were at high risk of bias, and had very low‐certainty evidence. </p> <p>The five included trials assessed five different comparisons of antibiotics.</p> <p>We did not conduct a meta‐analysis due to lack of relevant data.</p> <p>Of the five included trials one trial compared cefazolin plus amikacin with vancomycin plus amikacin; one trial compared ticarcillin plus clavulanic acid with flucloxacillin plus gentamicin; one trial compared cloxacillin plus amikacin with cefotaxime plus gentamicin; one trial compared meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin); and one trial compared vancomycin plus gentamicin with vancomycin plus aztreonam. </p> <p>None of the five comparisons found any evidence of a difference when assessing all‐cause mortality, serious adverse events, circulatory support, nephrotoxicity, neurological developmental impairment, or necrotising enterocolitis; however, none of the trials were near an information size that could contribute significantly to the evidence of the comparative benefits and risks of any particular antibiotic regimen. </p> <p>None of the trials assessed respiratory support or ototoxicity.</p> <p>The benefits and harms of different antibiotic regimens remain unclear due to the lack of well‐powered trials and the high risk of systematic errors. </p> </section> <section id="CD013836-sec-0007"> <h3 class="title" id="CD013836-sec-0007">Authors' conclusions</h3> <p>Current evidence is insufficient to support any antibiotic regimen being superior to another. RCTs assessing different antibiotic regimens in late‐onset neonatal sepsis with low risks of bias are warranted. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013836-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013836-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013836-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013836-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013836-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013836-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013836-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013836-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013836-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013836-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013836-abs-0002" lang="en"> <h3>Antibiotic regimens for late‐onset neonatal sepsis</h3> <p><b>Review question</b> </p> <p>We reviewed the available evidence on different antibiotic regimens for newborns (from 72 hours of life to one month of life) with late‐onset sepsis. </p> <p><b>Background</b> </p> <p>Sepsis in newborns is a severe and potential lethal condition, caused by the body's response to an infection. Neonatal sepsis is the third leading cause of neonatal death globally<i>.</i> Despite this high burden of sepsis in newborns, high‐quality evidence in diagnosis and treatment is scarce. This Cochrane Review was originally published in 2005. To identify the most appropriate antibiotic policies for neonatal sepsis, there is a need to base these policies on an updated well‐conducted review. Therefore, there is a need for such a review assessing the effects of different antibiotic regimens for late‐onset neonatal sepsis. </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to March 2021. We included five trials randomising 580 participants. The five trials compared five different antibiotic regimens. </p> <p><b>Key results</b> </p> <p>We included five trials: one trial compared cefazolin plus amikacin with vancomycin plus amikacin; one trial compared ticarcillin plus clavulanic acid with flucloxacillin plus gentamicin; one trial compared cloxacillin plus amikacin with cefotaxime plus gentamicin; one trial compared meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin); and one trial compared vancomycin plus gentamicin with vancomycin plus aztreonam. </p> <p>None of the five antibiotic comparisons showed that the choice of antibiotics influenced the effects on death from all‐causes, serious adverse events (i.e. major complications), circulatory support, nephrotoxicity (toxicity in the kidneys), neurological developmental impairment (disabilities in the functioning of the brain that affect a child's behaviour, memory, or ability to learn), or necrotising enterocolitis (tissues in the gut become inflamed and start to die). Current evidence cannot confirm or reject, one antibiotic regimen being superior to another due to scarce data. </p> <p><b>Quality of the evidence</b> </p> <p>Our conclusions are based on very low‐quality evidence. The five trials were at high risk of bias (i.e. the trials were conducted in a way that may have skewed results to the positive side). In addition, the five trials included few participants, making the results of this review imprecise. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013836-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013836-sec-0130"></div> <h3 class="title" id="CD013836-sec-0131">Implications for practice</h3> <section id="CD013836-sec-0131"> <p>Current evidence does not allow confirmation, or rejection, of one antibiotic regimen being superior to another. </p> </section> <h3 class="title" id="CD013836-sec-0132">Implications for research</h3> <section id="CD013836-sec-0132"> <p>The primary focus should be to develop an international consensus definition of neonatal sepsis (<a href="./references#CD013836-bbs2-0130" title="McGovernM , GiannoniE , KuesterH , TurnerMA , vanden HoogenA , BlissJM , et al. Challenges in developing a consensus definition of neonatal sepsis. Pediatric Research2020;88(1):14-26.">McGovern 2020</a>; <a href="./references#CD013836-bbs2-0194" title="WynnJL , WongHR , ShanleyTP , BizzarroMJ , SaimanL , PolinRA . Time for a neonatal-specific consensus definition for sepsis. Pediatric Critical Care Medicine2014;15(6):523-8. [DOI: 10.1097/PCC.0000000000000157] [PMID: 24751791]">Wynn 2014</a>; <a href="./references#CD013836-bbs2-0195" title="WynnJL . Defining neonatal sepsis. Current Opinion in Pediatrics2016;28(2):135-40. [DOI: 10.1097/MOP.0000000000000315] [PMID: 26766602]">Wynn 2016</a>). </p> <p>Then high‐quality randomised controlled trials are needed to assess the effects of different antibiotic regimens for sepsis in newborn infants. Such trials should: </p> <p> <ul id="CD013836-list-0015"> <li> <p>randomise a sufficient number of participants to demonstrate a reliable result;</p> </li> <li> <p>assess all‐cause mortality and serious adverse events;</p> </li> <li> <p>be conducted with low risk of bias;</p> </li> <li> <p>adhere to consensus definitions of suspected and diagnosed late‐onset neonatal when such emerge; </p> </li> <li> <p>measure antibiotic resistance among the culture‐positive participants;</p> </li> <li> <p>Assess differences between sites, countries, and regions included.</p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013836-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013836-sec-0008"></div> <div class="table" id="CD013836-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cefazolin plus amikacin compared with vancomycin plus amikacin for late‐onset neonatal sepsis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cefazolin + amikacin compared with vancomycin + amikacin for late‐onset neonatal sepsis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborns with late‐onset sepsis </p> <p><b>Settings:</b> neonatal intensive care unit in Argentina </p> <p><b>Intervention:</b> cefazolin + amikacin </p> <p><b>Comparison:</b> vancomycin + amikacin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Vancomycin + amikacin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cefazolin + amikacin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000<br/>(39 to 223) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b> </p> <p>(0.29 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 3022 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000<br/>(39 to 223) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b> </p> <p>(0.29 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 3022 (RR 0.80, α 0.05, β 0.20)</p> <p>Serious adverse events were deaths.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of very serious risk of bias, very serious imprecision of results, and serious risk of indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013836-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ticarcillin plus clavulanic acid compared with flucloxacillin and gentamicin for late‐onset neonatal sepsis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ticarcillin + clavulanic acid compared with flucloxacillin + gentamicin for late‐onset neonatal sepsis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborns with late‐onset sepsis </p> <p><b>Settings:</b> neonatal intensive care unit in England </p> <p><b>Intervention:</b> ticarcillin + clavulanic acid </p> <p><b>Comparison:</b> flucloxacillin + gentamicin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Flucloxacillin + gentamicin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Ticarcillin + clavulanic acid</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/>(1 to 546) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.20</b> </p> <p>(0.01 to 3.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 4306 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/>(1 to 546) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.20</b> </p> <p>(0.01 to 3.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 4306 (RR 0.80, α 0.05, β 0.20)</p> <p>Serious adverse events were deaths.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of very serious risk of bias, very serious imprecision of results, and serious risk of indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013836-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Cloxacillin plus amikacin compared with cefotaxime plus gentamicin for neonatal late‐onset sepsis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cloxacillin + amikacin compared with cefotaxime + gentamicin for neonatal late‐onset sepsis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborns with late‐onset sepsis </p> <p><b>Settings:</b> neonatal intensive care unit in India </p> <p><b>Intervention:</b> cloxacillin + amikacin </p> <p><b>Comparison:</b> cefotaxime + gentamicin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cefotaxime + gentamicin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cloxacillin + amikacin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000<br/>(22 to 254) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.38</b> </p> <p>(0.11 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 2894 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000<br/>(34 to 296) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> </p> <p>(0.17 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 2894 (RR 0.80, α 0.05, β 0.20)</p> <p>Serious adverse events were participants who developed shock.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Circulatory support</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000<br/>(34 to 296) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> </p> <p>(0.17 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 2894 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nephrotoxicity</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/>(3 to 205) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.25</b> </p> <p>(0.03 to 2.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 6428 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of very serious risk of bias, very serious imprecision of results, and serious risk of indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013836-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Meropenem compared with standard care for neonatal late‐onset sepsis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Meropenem compared with standard care for neonatal late‐onset sepsis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborns with late‐onset sepsis </p> <p><b>Settings:</b> neonatal intensive care units in Europe </p> <p><b>Intervention:</b> meropenem </p> <p><b>Comparison:</b> standard care (ampicillin + gentamicin or cefotaxime + gentamicin) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Meropenem</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Standard care</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/>(29 to 188) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.42</b> </p> <p>(0.56 to 3.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup> </p> <p><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 12976 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 1000<br/>(120 to 355) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.54</b> </p> <p>(0.90 to 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 4662 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurological developmental impairment</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>178 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155 per 1000<br/>(91 to 263) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> </p> <p>(0.51 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 3336 (RR 0.80, α 0.05, β 0.20)</p> <p>This outcome was number of participants with intracranial bleeding.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Necrotising enterocolitis</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/>(39 to 168) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.68</b> </p> <p>(0.33 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 5324 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CIS:</b> optimal information size; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of very serious risk of bias, very serious imprecision of results, and serious risk of indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013836-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Vancomycin plus gentamicin compared with vancomycin plus aztreonam for late‐onset neonatal sepsis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vancomycin + gentamicin compared with vancomycin + aztreonam for late‐onset neonatal sepsis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborns with late‐onset sepsis </p> <p><b>Settings:</b> neonatal intensive care units in England </p> <p><b>Intervention:</b> vancomycin + gentamicin </p> <p><b>Comparison:</b> vancomycin + aztreonam </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Vancomycin + aztreonam</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Vancomycin + gentamicin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000<br/>(30 to 320) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b> </p> <p>(0.20 to 2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 4072 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000<br/>(30 to 320) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b> </p> <p>(0.20 to 2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 4072 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Necrotising enterocolitis</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 12.69</b> </p> <p>(0.74 to 218.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NA:</b> not available; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of very serious risk of bias, very serious imprecision of results, and serious risk of indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013836-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013836-sec-0009"></div> <section id="CD013836-sec-0010"> <h3 class="title" id="CD013836-sec-0010">Description of the condition</h3> <section id="CD013836-sec-0011"> <h4 class="title">Definition</h4> <p>Sepsis is defined as a life‐threatening organ dysfunction caused by a dysregulated host response to infection (<a href="./references#CD013836-bbs2-0159" title="SingerM , DeutschmanCS , SeymourCW , Shankar-HariM , AnnaneD , BauerM , et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA2016;315(8):801-10. [DOI: 10.1001/jama.2016.0287] [PMID: 26903338]">Singer 2016</a>). There is currently no international consensus on specific criteria for neonatal sepsis (<a href="./references#CD013836-bbs2-0194" title="WynnJL , WongHR , ShanleyTP , BizzarroMJ , SaimanL , PolinRA . Time for a neonatal-specific consensus definition for sepsis. Pediatric Critical Care Medicine2014;15(6):523-8. [DOI: 10.1097/PCC.0000000000000157] [PMID: 24751791]">Wynn 2014</a>; <a href="./references#CD013836-bbs2-0195" title="WynnJL . Defining neonatal sepsis. Current Opinion in Pediatrics2016;28(2):135-40. [DOI: 10.1097/MOP.0000000000000315] [PMID: 26766602]">Wynn 2016</a>). The most used neonatal sepsis criteria in clinical trials are based on a combination of clinical and laboratory parameters (see <a href="#CD013836-tbl-0006">Table 1</a>) (<a href="./references#CD013836-bbs2-0136" title="MorrisJM , RobertsCL , BowenJR , PattersonJA , BondDM , AlgertCS , et al, PPROMT Collaboration. Immediate delivery compared with expectant management after preterm pre-labour rupture of the membranes close to term (PPROMT trial): a randomised controlled trial. Lancet2016;387(10017):444-52. [DOI: 10.1016/S0140-6736(15)00724-2] [PMID: 26564381]">Morris 2016</a>; <a href="./references#CD013836-bbs2-0194" title="WynnJL , WongHR , ShanleyTP , BizzarroMJ , SaimanL , PolinRA . Time for a neonatal-specific consensus definition for sepsis. Pediatric Critical Care Medicine2014;15(6):523-8. [DOI: 10.1097/PCC.0000000000000157] [PMID: 24751791]">Wynn 2014</a>). </p> <div class="table" id="CD013836-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Commonly used clinical and laboratory criteria of sepsis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Clinical criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Laboratory criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013836-list-0001"> <li> <p>Abdominal distension</p> </li> <li> <p>Skin and subcutaneous lesions such as petechial rash, abscesses, sclerema</p> </li> <li> <p>Cardiovascular signs (tachycardia/bradycardia, hypotension, poor perfusion)</p> </li> <li> <p>Respiratory signs (apnoea, cyanosis, tachypnoea, need for ventilator, increased oxygen requirement) </p> </li> <li> <p>Abnormal temperature (fever or hypothermia)</p> </li> <li> <p>Central nervous system signs (lethargy, hypotonia, seizure)</p> </li> <li> <p>Feeding problems</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013836-list-0002"> <li> <p>WBC</p> </li> <li> <p>Immature WBC:total WBC ratio</p> </li> <li> <p>Platelet count</p> </li> <li> <p>C‐reactive protein</p> </li> <li> <p>Metabolic acidosis</p> </li> <li> <p>Neutropenia</p> </li> <li> <p>Abnormal fibrinogen</p> </li> <li> <p>Hyperglycaemia and hypoglycaemia</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>WBC: white blood cell.</p> </div> </div> <p>Sepsis that occurs before 28 days after birth is termed neonatal sepsis (<a href="./references#CD013836-bbs2-0057" title="BakhuizenSE , deHaanTR , TeuneMJ , vanWassenaer-LeemhuisAG , van derHeydenJL , van derHamDP , et al. Meta-analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications. Acta Paediatrica2014;103(12):1211-8. [DOI: 10.1111/apa.12764] [PMID: 25073543]">Bakhuizen 2014</a>; <a href="./references#CD013836-bbs2-0071" title="Camacho-GonzalezA , SpearmanPW , StollBJ . Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatric Clinics of North America2013;60(2):367-89. [DOI: 10.1016/j.pcl.2012.12.003] [PMID: 23481106]">Camacho‐Gonzalez 2013</a>). Depending on the time of onset, neonatal sepsis is termed either early‐onset sepsis or late‐onset sepsis. The most accepted distinction between these two subgroups is cases occurring before 72 hours after birth and after 72 hours after birth, but other definitions exist (e.g. 48 hours and seven days after birth (<a href="./references#CD013836-bbs2-0057" title="BakhuizenSE , deHaanTR , TeuneMJ , vanWassenaer-LeemhuisAG , van derHeydenJL , van derHamDP , et al. Meta-analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications. Acta Paediatrica2014;103(12):1211-8. [DOI: 10.1111/apa.12764] [PMID: 25073543]">Bakhuizen 2014</a>; <a href="./references#CD013836-bbs2-0065" title="BizzarroMJ , DembryLM , BaltimoreRS , GallagherPG . Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics2008;121(4):689-96. [DOI: 10.1542/peds.2007-2171] [PMID: 18381532]">Bizzarro 2008</a>; <a href="./references#CD013836-bbs2-0071" title="Camacho-GonzalezA , SpearmanPW , StollBJ . Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatric Clinics of North America2013;60(2):367-89. [DOI: 10.1016/j.pcl.2012.12.003] [PMID: 23481106]">Camacho‐Gonzalez 2013</a>; <a href="./references#CD013836-bbs2-0125" title="MananMM , IbrahimNA , AzizNA , ZulkiflyHH , Al-WorafiYM , LongCM . Empirical use of antibiotic therapy in the prevention of early onset sepsis in neonates: a pilot study. Archives of Medical Science2016;12(3):603-13. [DOI: 10.5114/aoms.2015.51208] [PMID: 27279855]">Manan 2016</a>; <a href="./references#CD013836-bbs2-0036" title="MetsvahtT , IlmojaML , ParmU , MaipuuL , MerilaM , LutsarI . Comparison of ampicillin plus gentamicin vs penicillin plus gentamicin in empiric treatment of neonates at risk of early onset sepsis. Acta Paediatrica, International Journal of Paediatrics2010;99(5):665-72. [DOI: 10.1111/j.1651-2227.2010.01687.x] [PMID: 20096030]MetsvahtT , IlmojaML , ParmU , MerilaM , MaipuuL , MuurseppP , et al. Ampicillin versus penicillin in the empiric therapy of extremely low-birthweight neonates at risk of early onset sepsis. Pediatrics International2011;53(6):873-80. [DOI: 10.1111/j.1442-200X.2011.03468.x] [PMID: 21895866]ParmU , MetsvahtT , SeppE , IlmojaML , PisarevH , PauskarM , et al. Impact of empiric antibiotic regimen on bowel colonization in neonates with suspected early onset sepsis. European Journal of Clinical Microbiology &amp; Infectious Diseases2010;29(7):807-16. [DOI: 10.1007/s10096-010-0931-1] [PMID: 20446013]">Metsvaht 2010</a>; <a href="./references#CD013836-bbs2-0155" title="ShahBA , PadburyJF . Neonatal sepsis: an old problem with new insights. Virulence2014;5(1):170-8. [DOI: 10.4161/viru.26906] [PMID: 24185532]">Shah 2014</a>; <a href="./references#CD013836-bbs2-0156" title="ShaneAL , StollBJ . Recent developments and current issues in the epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis. American Journal of Perinatology2013;30(2):131-41. [DOI: 10.1055/s-0032-1333413] [PMID: 23297182]">Shane 2013</a>; <a href="./references#CD013836-bbs2-0157" title="ShaneAL , StollBJ . Neonatal sepsis: progress towards improved outcomes. Journal of Infection2014;68(Suppl 1):S24-32. [DOI: 10.1016/j.jinf.2013.09.011] [PMID: 24140138]">Shane 2014</a>; <a href="./references#CD013836-bbs2-0175" title="TripathiN , CottenCM , SmithPB . Antibiotic use and misuse in the neonatal intensive care unit. Clinics in Perinatology2012;39(1):61-8. [DOI: 10.1016/j.clp.2011.12.003] [PMID: 22341537]">Tripathi 2012</a>; <a href="./references#CD013836-bbs2-0198" title="ZaidiAK , ThaverD , AliSA , KhanTA . Pathogens associated with sepsis in newborns and young infants in developing countries. Pediatric Infectious Disease Journal2009;28(1 Suppl):S10-8. [DOI: 10.1097/INF.0b013e3181958769] [PMID: 19106757]">Zaidi 2009</a>; <a href="./references#CD013836-bbs2-0199" title="Zea-VeraA , OchoaTJ . Challenges in the diagnosis and management of neonatal sepsis. Journal of Tropical Pediatrics2015;61(1):1-13. [DOI: 10.1093/tropej/fmu079] [PMID: 25604489]">Zea‐Vera 2015</a>). This distinction is based on the different aetiologies and pathophysiology of pathogens typically seen before and after 72 hours of age (<a href="./references#CD013836-bbs2-0071" title="Camacho-GonzalezA , SpearmanPW , StollBJ . Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatric Clinics of North America2013;60(2):367-89. [DOI: 10.1016/j.pcl.2012.12.003] [PMID: 23481106]">Camacho‐Gonzalez 2013</a>; <a href="./references#CD013836-bbs2-0036" title="MetsvahtT , IlmojaML , ParmU , MaipuuL , MerilaM , LutsarI . Comparison of ampicillin plus gentamicin vs penicillin plus gentamicin in empiric treatment of neonates at risk of early onset sepsis. Acta Paediatrica, International Journal of Paediatrics2010;99(5):665-72. [DOI: 10.1111/j.1651-2227.2010.01687.x] [PMID: 20096030]MetsvahtT , IlmojaML , ParmU , MerilaM , MaipuuL , MuurseppP , et al. Ampicillin versus penicillin in the empiric therapy of extremely low-birthweight neonates at risk of early onset sepsis. Pediatrics International2011;53(6):873-80. [DOI: 10.1111/j.1442-200X.2011.03468.x] [PMID: 21895866]ParmU , MetsvahtT , SeppE , IlmojaML , PisarevH , PauskarM , et al. Impact of empiric antibiotic regimen on bowel colonization in neonates with suspected early onset sepsis. European Journal of Clinical Microbiology &amp; Infectious Diseases2010;29(7):807-16. [DOI: 10.1007/s10096-010-0931-1] [PMID: 20446013]">Metsvaht 2010</a>; <a href="./references#CD013836-bbs2-0155" title="ShahBA , PadburyJF . Neonatal sepsis: an old problem with new insights. Virulence2014;5(1):170-8. [DOI: 10.4161/viru.26906] [PMID: 24185532]">Shah 2014</a>; <a href="./references#CD013836-bbs2-0156" title="ShaneAL , StollBJ . Recent developments and current issues in the epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis. American Journal of Perinatology2013;30(2):131-41. [DOI: 10.1055/s-0032-1333413] [PMID: 23297182]">Shane 2013</a>). </p> <p>Late‐onset sepsis frequently presents with clinical deterioration including apnoea, tachypnoea, increased ventilatory requirement, hypotension, abnormal heart rate, hyperglycaemia, abnormal temperature (hypothermia or hyperthermia), cyanosis, acidosis, feeding intolerance, abdominal distension, lethargy, and skin mottling (<a href="./references#CD013836-bbs2-0080" title="CraftAP , FinerNN , BarringtonKJ . Vancomycin for prophylaxis against sepsis in preterm neonates. Cochrane Database of Systematic Reviews2000, Issue 1. Art. No: CD001971. [DOI: 10.1002/14651858.CD001971]">Craft 2000</a>; <a href="./references#CD013836-bbs2-0178" title="TsaiMH , HsuJF , ChuSM , LienR , HuangHR , ChiangMC , et al. Incidence, clinical characteristics and risk factors for adverse outcome in neonates with late-onset sepsis. Pediatric Infectious Disease Journal2014;33(1):e7-13. [DOI: 10.1097/INF.0b013e3182a72ee0] [PMID: 23899966]">Tsai 2014</a>). As some of these clinical manifestations can be non‐specific, it can be difficult to clinically distinguish between sepsis and deep‐seated infections, such as meningitis, osteomyelitis, and necrotising enterocolitis (NEC) (<a href="./references#CD013836-bbs2-0071" title="Camacho-GonzalezA , SpearmanPW , StollBJ . Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatric Clinics of North America2013;60(2):367-89. [DOI: 10.1016/j.pcl.2012.12.003] [PMID: 23481106]">Camacho‐Gonzalez 2013</a>; <a href="./references#CD013836-bbs2-0199" title="Zea-VeraA , OchoaTJ . Challenges in the diagnosis and management of neonatal sepsis. Journal of Tropical Pediatrics2015;61(1):1-13. [DOI: 10.1093/tropej/fmu079] [PMID: 25604489]">Zea‐Vera 2015</a>). </p> </section> <section id="CD013836-sec-0012"> <h4 class="title">Epidemiology</h4> <p>Since there is neither consensus on criteria for neonatal sepsis nor agreement on the cut‐off between early‐onset and late‐onset sepsis (48 hours, 72 hours, or seven days) (see 'Definition' section above), it is difficult to estimate the exact incidence of neonatal sepsis (<a href="./references#CD013836-bbs2-0057" title="BakhuizenSE , deHaanTR , TeuneMJ , vanWassenaer-LeemhuisAG , van derHeydenJL , van derHamDP , et al. Meta-analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications. Acta Paediatrica2014;103(12):1211-8. [DOI: 10.1111/apa.12764] [PMID: 25073543]">Bakhuizen 2014</a>). Studies from the USA and Australia suggest that late‐onset sepsis constitutes 3 per 1000 to 6 per 1000 live births, while early‐onset sepsis ranges from 0.9 per 1000 to 3.5 per 1000 live births (<a href="./references#CD013836-bbs2-0107" title="IsaacsD , RoyleJA . Intrapartum antibiotics and early onset neonatal sepsis caused by group B Streptococcus and by other organisms in Australia. Australasian Study Group for Neonatal Infections. Pediatric Infectious Disease Journal1999;18(6):524-8. [DOI: 10.1097/00006454-199906000-00009] [PMID: 10391182]">Isaacs 1999</a>; <a href="./references#CD013836-bbs2-0150" title="SchuchatA , ZywickiSS , DinsmoorMJ , MercerB , RomagueraJ , O'SullivanMJ , et al. Risk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study. Pediatrics2000;105(1 Pt 1):21-6. [DOI: 10.1542/peds.105.1.21] [PMID: 10617699]">Schuchat 2000</a>; <a href="./references#CD013836-bbs2-0179" title="VergnanoS , SharlandM , KazembeP , MwansamboC , HeathPT . Neonatal sepsis: an international perspective. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90(3):F220-4. [DOI: 10.1136/adc.2002.022863] [PMID: 15846011]">Vergnano 2005</a>; <a href="./references#CD013836-bbs2-0180" title="VergnanoS , MensonE , KenneaN , EmbletonN , RussellAB , WattsT , et al. Neonatal infections in England: the NeonIN surveillance network. Archives of Disease in Childhood. Fetal and Neonatal Edition2011;96(1):F9-14. [DOI: 10.1136/adc.2009.178798] [PMID: 20876594]">Vergnano 2011</a>). </p> <p>Late‐onset sepsis is believed to be more common in preterm (less than 37 weeks' gestation) and low birthweight (less than 2500 g) neonates (<a href="./references#CD013836-bbs2-0168" title="StollBJ , HansenNI , SánchezPJ , FaixRG , PoindexterBB , vanMeursKP , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics2011;127(5):817-26. [DOI: 10.1542/peds.2010-2217] [PMID: 21518717]">Stoll 2011</a>; <a href="./references#CD013836-bbs2-0178" title="TsaiMH , HsuJF , ChuSM , LienR , HuangHR , ChiangMC , et al. Incidence, clinical characteristics and risk factors for adverse outcome in neonates with late-onset sepsis. Pediatric Infectious Disease Journal2014;33(1):e7-13. [DOI: 10.1097/INF.0b013e3182a72ee0] [PMID: 23899966]">Tsai 2014</a>). Large non‐randomised studies suggest that late‐onset sepsis has decreased significantly in recent decades in high‐income countries (<a href="./references#CD013836-bbs2-0101" title="HorbarJD , EdwardsEM , GreenbergLT , MorrowKA , SollRF , Buus-FrankME , et al. Variation in performance of neonatal intensive care units in the United States. JAMA Pediatrics2017;171(3):e164396.">Horbar 2017</a>; <a href="./references#CD013836-bbs2-0169" title="StollBJ , HansenNI , BellEF , WalshMC , CarloWA , ShankaranS , et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA2015;314(10):1039-51.">Stoll 2015</a>). </p> <p>Neonatal sepsis is a major cause of morbidity and mortality. It is the third leading cause of neonatal mortality globally, constituting 13% of overall neonatal mortality (<a href="./references#CD013836-bbs2-0119" title="LawnJE , CousensS , ZupanJ , Lancet Neonatal Survival Steering Team. 4 million neonatal deaths: when? Where? Why?Lancet2005;365(9462):891-900. [DOI: 10.1016/S0140-6736(05)71048-5] [PMID: 15752534]">Lawn 2005</a>; <a href="./references#CD013836-bbs2-0123" title="LiuL , JohnsonHL , CousensS , PerinJ , ScottS , LawnJE , et al, Child Health Epidemiology Reference Group of WHO and UNICEF . Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet2012;379(9832):2151-61; Erratum in: Lancet 2012;380(9850):1308. [DOI: 10.1016/S0140-6736(12)60560-1] [PMID: 22579125]">Liu 2012</a>). In high‐income countries, the mortality rate due to neonatal sepsis ranges from 5% to 20%, and neonatal sepsis results in major disability or death in 39% of all cases despite initiation of conventional treatment. Mortality rates higher than 70% can be observed in some low‐ and middle‐income countries (LMICs) (<a href="./references#CD013836-bbs2-0057" title="BakhuizenSE , deHaanTR , TeuneMJ , vanWassenaer-LeemhuisAG , van derHeydenJL , van derHamDP , et al. Meta-analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications. Acta Paediatrica2014;103(12):1211-8. [DOI: 10.1111/apa.12764] [PMID: 25073543]">Bakhuizen 2014</a>; <a href="./references#CD013836-bbs2-0111" title="KabweM , TemboJ , ChilukutuL , ChilufyaM , NgulubeF , LukwesaC , et al. Etiology, antibiotic resistance and risk factors for neonatal sepsis in a large referral center in Zambia. Pediatric Infectious Disease Journal2016;35(7):e191-8. [DOI: 10.1097/INF.0000000000001154] [PMID: 27031259]">Kabwe 2016</a>; <a href="./references#CD013836-bbs2-0187" title="WestonEJ , PondoT , LewisMM , Martell-ClearyP , MorinC , JewellB , et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatric Infectious Disease Journal2011;30(11):937-41. [DOI: 10.1097/INF.0b013e318223bad2] [PMID: 21654548]">Weston 2011</a>; <a href="./references#CD013836-bbs2-0194" title="WynnJL , WongHR , ShanleyTP , BizzarroMJ , SaimanL , PolinRA . Time for a neonatal-specific consensus definition for sepsis. Pediatric Critical Care Medicine2014;15(6):523-8. [DOI: 10.1097/PCC.0000000000000157] [PMID: 24751791]">Wynn 2014</a>). </p> <p>Sepsis during the neonatal period can result in several complications, such as multiple organ failure, cerebral haemorrhage, periventricular leukomalacia, meningitis, and respiratory distress syndrome (<a href="./references#CD013836-bbs2-0158" title="SharmaR , Tepas JJ 3rd, HudakML , MollittDL , WludykaPS , TengRJ , et al. Neonatal gut barrier and multiple organ failure: role of endotoxin and proinflammatory cytokines in sepsis and necrotizing enterocolitis. Journal of Pediatric Surgery2007;42(3):454-61. [DOI: 10.1016/j.jpedsurg.2006.10.038] [PMID: 17336180]">Sharma 2007</a>; <a href="./references#CD013836-bbs2-0167" title="StollBJ , HansenNI , BellEF , ShankaranS , LaptookAR , WalshMC , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics2010;126(3):443-56. [DOI: 10.1542/peds.2009-2959] [PMID: 20732945]">Stoll 2010</a>). In survivors, sepsis is associated with serious long‐term morbidity, such as cerebral palsy, cognitive and psychomotor delay, auditory and visual impairment, and bronchopulmonary dysplasia (<a href="./references#CD013836-bbs2-0057" title="BakhuizenSE , deHaanTR , TeuneMJ , vanWassenaer-LeemhuisAG , van derHeydenJL , van derHamDP , et al. Meta-analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications. Acta Paediatrica2014;103(12):1211-8. [DOI: 10.1111/apa.12764] [PMID: 25073543]">Bakhuizen 2014</a>; <a href="./references#CD013836-bbs2-0061" title="Benjamin DK Jr, StollBJ , FanaroffAA , McDonaldSA , OhW , HigginsRD , et al, National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics2006;117(1):84-92. [DOI: 10.1542/peds.2004-2292] [PMID: 16396864]">Benjamin 2006</a>; <a href="./references#CD013836-bbs2-0115" title="KlingerG , LevyI , SirotaL , BoykoV , Lerner-GevaL , ReichmanB , Israel Neonatal Network. Outcome of early-onset sepsis in a national cohort of very low birth weight infants. Pediatrics2010;125(4):e736-40. [DOI: 10.1542/peds.2009-2017] [PMID: 20231184]">Klinger 2010</a>; <a href="./references#CD013836-bbs2-0149" title="SchlapbachLJ , AebischerM , AdamsM , NatalucciG , BonhoefferJ , LatzinP , et al, Swiss Neonatal Network and Follow-Up Group. Impact of sepsis on neurodevelopmental outcome in a Swiss National Cohort of extremely premature infants. Pediatrics2011;128(2):e348-57. [DOI: 10.1542/peds.2010-3338] [PMID: 21768312]">Schlapbach 2011</a>). Most of these associations are based on observational cohort studies and therefore do not distinguish between causality and association. It remains uncertain whether it is possible to prevent these subsequent sequela by treating neonatal sepsis with an appropriate empirical antibiotic regimen (<a href="./references#CD013836-bbs2-0057" title="BakhuizenSE , deHaanTR , TeuneMJ , vanWassenaer-LeemhuisAG , van derHeydenJL , van derHamDP , et al. Meta-analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications. Acta Paediatrica2014;103(12):1211-8. [DOI: 10.1111/apa.12764] [PMID: 25073543]">Bakhuizen 2014</a>). </p> </section> <section id="CD013836-sec-0013"> <h4 class="title">Aetiology</h4> <p>The pathogens that cause late‐onset sepsis include Gram‐positive and Gram‐negative bacteria, as well as fungal infections (<a href="./references#CD013836-bbs2-0067" title="BoghossianNS , PageGP , BellEF , StollBJ , MurrayJC , CottenCM , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Late-onset sepsis in very low birth weight infants from singleton and multiple-gestation births. Journal of Pediatrics2013;162(6):1120-4, 1124.e1. [DOI: 10.1016/j.jpeds.2012.11.089] [PMID: 23324523]">Boghossian 2013</a>). The mortality and the distribution pattern of pathogens that cause late‐onset infection differ between LMICs and high‐income countries. Important variations may be observed within and between individual neonatal intensive care units (NICUs) in each country. The predominant organisms responsible for neonatal sepsis within regions have also changed over time (<a href="./references#CD013836-bbs2-0084" title="DongY , SpeerCP . Late-onset neonatal sepsis: recent developments. Archives of Disease in Childhood. Fetal and Neonatal Edition2015;100(3):F257-63. [DOI: 10.1136/archdischild-2014-306213] [PMID: 25425653]">Dong 2015</a>; <a href="./references#CD013836-bbs2-0163" title="StollBJ , GordonT , KoronesSB , ShankaranS , TysonJE , BauerCR , et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. Journal of Pediatrics1996;129(1):63-71. [DOI: 10.1016/s0022-3476(96)70191-9] [PMID: 8757564]">Stoll 1996</a>). </p> <p>The most common aetiological pathogen responsible for late‐onset sepsis is coagulase‐negative staphylococci, constituting 53% to 78% of all cases of late‐onset sepsis in high‐income countries (<a href="./references#CD013836-bbs2-0064" title="BizzarroMJ , RaskindC , BaltimoreRS , GallagherPG . Seventy-five years of neonatal sepsis at Yale: 1928-2003. Pediatrics2005;116(3):595-602. [DOI: 10.1542/peds.2005-0552] [PMID: 16140698]">Bizzarro 2005</a>; <a href="./references#CD013836-bbs2-0065" title="BizzarroMJ , DembryLM , BaltimoreRS , GallagherPG . Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics2008;121(4):689-96. [DOI: 10.1542/peds.2007-2171] [PMID: 18381532]">Bizzarro 2008</a>; <a href="./references#CD013836-bbs2-0084" title="DongY , SpeerCP . Late-onset neonatal sepsis: recent developments. Archives of Disease in Childhood. Fetal and Neonatal Edition2015;100(3):F257-63. [DOI: 10.1136/archdischild-2014-306213] [PMID: 25425653]">Dong 2015</a>; <a href="./references#CD013836-bbs2-0106" title="IsaacsD , BarfieldC , ClothierT , DarlowB , DiplockR , EhrlichJ , et al. Late-onset infections of infants in neonatal units. Journal of Paediatrics and Child Health1996;32(2):158-61. [ 10.1111/j.1440-1754.1996.tb00914.x] [PMID: 9156527]">Isaacs 1996</a>; <a href="./references#CD013836-bbs2-0146" title="RubinLG , SánchezPJ , SiegelJ , LevineG , SaimanL , JarvisWR , Pediatric Prevention Network. Evaluation and treatment of neonates with suspected late onset sepsis: a survey of neonatologists' practices. Pediatrics2002;110(4):e42. [DOI: 10.1542/peds.110.4.e42] [PMID: 12359815]">Rubin 2002</a>; <a href="./references#CD013836-bbs2-0168" title="StollBJ , HansenNI , SánchezPJ , FaixRG , PoindexterBB , vanMeursKP , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics2011;127(5):817-26. [DOI: 10.1542/peds.2010-2217] [PMID: 21518717]">Stoll 2011</a>; <a href="./references#CD013836-bbs2-0187" title="WestonEJ , PondoT , LewisMM , Martell-ClearyP , MorinC , JewellB , et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatric Infectious Disease Journal2011;30(11):937-41. [DOI: 10.1097/INF.0b013e318223bad2] [PMID: 21654548]">Weston 2011</a>). However, since coagulase‐negative staphylococci are skin commensals, these organisms are also common blood culture contaminants and there is a lack of consensus regarding how to interpret blood cultures that are positive for coagulase‐negative staphylococci (<a href="./references#CD013836-bbs2-0146" title="RubinLG , SánchezPJ , SiegelJ , LevineG , SaimanL , JarvisWR , Pediatric Prevention Network. Evaluation and treatment of neonates with suspected late onset sepsis: a survey of neonatologists' practices. Pediatrics2002;110(4):e42. [DOI: 10.1542/peds.110.4.e42] [PMID: 12359815]">Rubin 2002</a>; <a href="./references#CD013836-bbs2-0186" title="WeinsteinMP . Blood culture contamination: persisting problems and partial progress. Journal of Clinical Microbiology2003;41(6):2275-8. [DOI: 10.1128/jcm.41.6.2275-2278.2003] [PMID: 12791835]">Weinstein 2003</a>). Other bacteria prevalent in late‐onset sepsis are <i>Escherichia coli</i> , group B <i>Streptococcus</i> , <i>Klebsiella pneumoniae</i> , <i>Enterococcus</i> , <i>Candida</i> , and <i>Pseudomonas</i> (<a href="./references#CD013836-bbs2-0106" title="IsaacsD , BarfieldC , ClothierT , DarlowB , DiplockR , EhrlichJ , et al. Late-onset infections of infants in neonatal units. Journal of Paediatrics and Child Health1996;32(2):158-61. [ 10.1111/j.1440-1754.1996.tb00914.x] [PMID: 9156527]">Isaacs 1996</a>; <a href="./references#CD013836-bbs2-0146" title="RubinLG , SánchezPJ , SiegelJ , LevineG , SaimanL , JarvisWR , Pediatric Prevention Network. Evaluation and treatment of neonates with suspected late onset sepsis: a survey of neonatologists' practices. Pediatrics2002;110(4):e42. [DOI: 10.1542/peds.110.4.e42] [PMID: 12359815]">Rubin 2002</a>; <a href="./references#CD013836-bbs2-0168" title="StollBJ , HansenNI , SánchezPJ , FaixRG , PoindexterBB , vanMeursKP , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics2011;127(5):817-26. [DOI: 10.1542/peds.2010-2217] [PMID: 21518717]">Stoll 2011</a>; <a href="./references#CD013836-bbs2-0180" title="VergnanoS , MensonE , KenneaN , EmbletonN , RussellAB , WattsT , et al. Neonatal infections in England: the NeonIN surveillance network. Archives of Disease in Childhood. Fetal and Neonatal Edition2011;96(1):F9-14. [DOI: 10.1136/adc.2009.178798] [PMID: 20876594]">Vergnano 2011</a>). </p> <p>In LMICs, coagulase‐negative staphylococci are still very common, constituting 36% to 47% of all cases of late‐onset sepsis (<a href="./references#CD013836-bbs2-0084" title="DongY , SpeerCP . Late-onset neonatal sepsis: recent developments. Archives of Disease in Childhood. Fetal and Neonatal Edition2015;100(3):F257-63. [DOI: 10.1136/archdischild-2014-306213] [PMID: 25425653]">Dong 2015</a>; <a href="./references#CD013836-bbs2-0096" title="HammoudMS , Al-TaiarA , ThalibL , Al-SweihN , PathanS , IsaacsD . Incidence, aetiology and resistance of late-onset neonatal sepsis: a five-year prospective study. Journal of Paediatrics and Child Health2012;48(7):604-9. [DOI: 10.1111/j.1440-1754.2012.02432.x] [PMID: 22404730]">Hammoud 2012</a>). The second most common Gram‐positive pathogen is <i>Staphylococcus aureus</i> (<a href="./references#CD013836-bbs2-0084" title="DongY , SpeerCP . Late-onset neonatal sepsis: recent developments. Archives of Disease in Childhood. Fetal and Neonatal Edition2015;100(3):F257-63. [DOI: 10.1136/archdischild-2014-306213] [PMID: 25425653]">Dong 2015</a>; <a href="./references#CD013836-bbs2-0197" title="ZaidiAK , HuskinsWC , ThaverD , BhuttaZA , AbbasZ , GoldmannDA . Hospital-acquired neonatal infections in developing countries. Lancet2005;365(9465):1175-88. [DOI: 10.1016/S0140-6736(05)71881-X] [PMID: 15794973]">Zaidi 2005</a>). Gram‐negative pathogens are relatively more common in LMICs (<a href="./references#CD013836-bbs2-0084" title="DongY , SpeerCP . Late-onset neonatal sepsis: recent developments. Archives of Disease in Childhood. Fetal and Neonatal Edition2015;100(3):F257-63. [DOI: 10.1136/archdischild-2014-306213] [PMID: 25425653]">Dong 2015</a>; <a href="./references#CD013836-bbs2-0197" title="ZaidiAK , HuskinsWC , ThaverD , BhuttaZA , AbbasZ , GoldmannDA . Hospital-acquired neonatal infections in developing countries. Lancet2005;365(9465):1175-88. [DOI: 10.1016/S0140-6736(05)71881-X] [PMID: 15794973]">Zaidi 2005</a>). The most frequent Gram‐negative pathogens are <i>Klebsiella</i> species, <i>E coli</i> , <i>Pseudomonas</i> , and <i>Salmonella</i> species (<a href="./references#CD013836-bbs2-0068" title="BreurecS , BouchiatC , SireJM , MoquetO , BercionR , CisseMF , et al. High third-generation cephalosporin resistant Enterobacteriaceae prevalence rate among neonatal infections in Dakar, Senegal. BMC Infectious Diseases2016;16(1):587. [DOI: 10.1186/s12879-016-1935-y] [PMID: 27765017]">Breurec 2016</a>; <a href="./references#CD013836-bbs2-0096" title="HammoudMS , Al-TaiarA , ThalibL , Al-SweihN , PathanS , IsaacsD . Incidence, aetiology and resistance of late-onset neonatal sepsis: a five-year prospective study. Journal of Paediatrics and Child Health2012;48(7):604-9. [DOI: 10.1111/j.1440-1754.2012.02432.x] [PMID: 22404730]">Hammoud 2012</a>; <a href="./references#CD013836-bbs2-0179" title="VergnanoS , SharlandM , KazembeP , MwansamboC , HeathPT . Neonatal sepsis: an international perspective. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90(3):F220-4. [DOI: 10.1136/adc.2002.022863] [PMID: 15846011]">Vergnano 2005</a>; <a href="./references#CD013836-bbs2-0191" title="World Health Organization Young Infants Study Group. Bacterial etiology of serious infections in young infants in developing countries: results of a multicenter study. Pediatric Infectious Disease Journal1999;18(10 Suppl):S17-22. [DOI: 10.1097/00006454-199910001-00004] [PMID: 10530569]">WHO 1999</a>; <a href="./references#CD013836-bbs2-0197" title="ZaidiAK , HuskinsWC , ThaverD , BhuttaZA , AbbasZ , GoldmannDA . Hospital-acquired neonatal infections in developing countries. Lancet2005;365(9465):1175-88. [DOI: 10.1016/S0140-6736(05)71881-X] [PMID: 15794973]">Zaidi 2005</a>). The pathogen with the highest case fatality ratio is considered to be <i>Pseudomonas aeruginosa</i> (<a href="./references#CD013836-bbs2-0096" title="HammoudMS , Al-TaiarA , ThalibL , Al-SweihN , PathanS , IsaacsD . Incidence, aetiology and resistance of late-onset neonatal sepsis: a five-year prospective study. Journal of Paediatrics and Child Health2012;48(7):604-9. [DOI: 10.1111/j.1440-1754.2012.02432.x] [PMID: 22404730]">Hammoud 2012</a>; <a href="./references#CD013836-bbs2-0178" title="TsaiMH , HsuJF , ChuSM , LienR , HuangHR , ChiangMC , et al. Incidence, clinical characteristics and risk factors for adverse outcome in neonates with late-onset sepsis. Pediatric Infectious Disease Journal2014;33(1):e7-13. [DOI: 10.1097/INF.0b013e3182a72ee0] [PMID: 23899966]">Tsai 2014</a>). </p> <p>Late‐onset sepsis has several risk factors. Major risk factors are immaturity, mechanical ventilation, intravascular catheterisation, failure of early enteral feeding with breast milk, prolonged duration of parenteral nutrition, surgery, underlying respiratory and cardiovascular diseases, and hospitalisation (<a href="./references#CD013836-bbs2-0067" title="BoghossianNS , PageGP , BellEF , StollBJ , MurrayJC , CottenCM , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Late-onset sepsis in very low birth weight infants from singleton and multiple-gestation births. Journal of Pediatrics2013;162(6):1120-4, 1124.e1. [DOI: 10.1016/j.jpeds.2012.11.089] [PMID: 23324523]">Boghossian 2013</a>; <a href="./references#CD013836-bbs2-0120" title="LealYA , Álvarez-NemegyeiJ , VelázquezJR , Rosado-QuiabU , Diego-RodríguezN , Paz-BaezaE , et al. Risk factors and prognosis for neonatal sepsis in southeastern Mexico: analysis of a four-year historic cohort follow-up. BMC Pregnancy and Childbirth2012;12:48. [DOI: 10.1186/1471-2393-12-48] [PMID: 22691696]">Leal 2012</a>; <a href="./references#CD013836-bbs2-0164" title="StollBJ , HansenN , FanaroffAA , WrightLL , CarloWA , EhrenkranzRA , et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics2002;110(2 Pt 1):285-91. [DOI: 10.1542/peds.110.2.285] [PMID: 12165580]">Stoll 2002</a>; <a href="./references#CD013836-bbs2-0176" title="TrögerB , GöpelW , FaustK , MüllerT , JorchG , Felderhoff-MüserU , et al, German Neonatal Network. Risk for late-onset blood-culture proven sepsis in very-low-birth weight infants born small for gestational age: a large multicenter study from the German Neonatal Network. Pediatric Infectious Disease Journal2014;33(3):238-43. [DOI: 10.1097/INF.0000000000000031] [PMID: 24030351]">Tröger 2014</a>; <a href="./references#CD013836-bbs2-0178" title="TsaiMH , HsuJF , ChuSM , LienR , HuangHR , ChiangMC , et al. Incidence, clinical characteristics and risk factors for adverse outcome in neonates with late-onset sepsis. Pediatric Infectious Disease Journal2014;33(1):e7-13. [DOI: 10.1097/INF.0b013e3182a72ee0] [PMID: 23899966]">Tsai 2014</a>). Furthermore, neonates are theoretically immunocompromised as several components of the immune system are not fully developed at birth (<a href="./references#CD013836-bbs2-0071" title="Camacho-GonzalezA , SpearmanPW , StollBJ . Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatric Clinics of North America2013;60(2):367-89. [DOI: 10.1016/j.pcl.2012.12.003] [PMID: 23481106]">Camacho‐Gonzalez 2013</a>; <a href="./references#CD013836-bbs2-0116" title="KumarSK , BhatBV . Distinct mechanisms of the newborn innate immunity. Immunology Letters2016;173:42-54. [DOI: 10.1016/j.imlet.2016.03.009] [PMID: 26994839]">Kumar 2016</a>). Preterm neonates are especially immunocompromised due to even more immature innate and adaptive immune systems (<a href="./references#CD013836-bbs2-0112" title="KanB , RazzaghianHR , LavoiePM . An immunological perspective on neonatal sepsis. Trends in Molecular Medicine2016;22(4):290-302. [DOI: 10.1016/j.molmed.2016.02.001] [PMID: 26993220]">Kan 2016</a>; <a href="./references#CD013836-bbs2-0145" title="RogoschT , KerzelS , HossK , HoerschG , ZemlinC , HeckmannM , et al. IgA response in preterm neonates shows little evidence of antigen-driven selection. Journal of Immunology2012;189(11):5449-56. [DOI: 10.4049/jimmunol.1103347] [PMID: 23105134]">Rogosch 2012</a>; <a href="./references#CD013836-bbs2-0184" title="WalkerJC , SmoldersMA , GemenEF , AntoniusTA , LeuveninkJ , deVriesE . Development of lymphocyte subpopulations in preterm infants. Scandinavian Journal of Immunology2011;73(1):53-8. [DOI: 10.1111/j.1365-3083.2010.02473.x] [PMID: 21129003]">Walker 2011</a>; <a href="./references#CD013836-bbs2-0196" title="YgbergS , NilssonA . The developing immune system – from foetus to toddler. Acta Paediatrica2012;101(2):120-7. [DOI: 10.1111/j.1651-2227.2011.02494.x] [PMID: 22003882]">Ygberg 2012</a>; <a href="./references#CD013836-bbs2-0200" title="ZemlinM , HoerschG , ZemlinC , Pohl-SchickingerA , HummelM , BerekC , et al. The postnatal maturation of the immunoglobulin heavy chain IgG repertoire in human preterm neonates is slower than in term neonates. Journal of Immunology2007;178(2):1180-8. [DOI: 10.4049/jimmunol.178.2.1180] [PMID: 17202383]">Zemlin 2007</a>). </p> </section> </section> <section id="CD013836-sec-0014"> <h3 class="title" id="CD013836-sec-0014">Description of the intervention</h3> <p>Antibiotics are antimicrobial drugs that treat and prevent bacterial infections by either killing the bacteria or inhibiting their growth (<a href="./references#CD013836-bbs2-0183" title="WaksmanSA . What is an antibiotic or an antibiotic substance?Mycologia1947;39(5):565-9. [DOI: 10.1056/NEJM194712042372302.] [PMID: 20264541]">Waksman 1947</a>). Early initiation of antibiotic therapy on neonates with suspected sepsis reduces both mortality and morbidity (<a href="./references#CD013836-bbs2-0057" title="BakhuizenSE , deHaanTR , TeuneMJ , vanWassenaer-LeemhuisAG , van derHeydenJL , van derHamDP , et al. Meta-analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications. Acta Paediatrica2014;103(12):1211-8. [DOI: 10.1111/apa.12764] [PMID: 25073543]">Bakhuizen 2014</a>). The choice of antibiotic used is often empirical and based on several factors, such as age at onset, likely pathogens, and antibiotic susceptibility patterns (<a href="./references#CD013836-bbs2-0084" title="DongY , SpeerCP . Late-onset neonatal sepsis: recent developments. Archives of Disease in Childhood. Fetal and Neonatal Edition2015;100(3):F257-63. [DOI: 10.1136/archdischild-2014-306213] [PMID: 25425653]">Dong 2015</a>; <a href="./references#CD013836-bbs2-0125" title="MananMM , IbrahimNA , AzizNA , ZulkiflyHH , Al-WorafiYM , LongCM . Empirical use of antibiotic therapy in the prevention of early onset sepsis in neonates: a pilot study. Archives of Medical Science2016;12(3):603-13. [DOI: 10.5114/aoms.2015.51208] [PMID: 27279855]">Manan 2016</a>; <a href="./references#CD013836-bbs2-0146" title="RubinLG , SánchezPJ , SiegelJ , LevineG , SaimanL , JarvisWR , Pediatric Prevention Network. Evaluation and treatment of neonates with suspected late onset sepsis: a survey of neonatologists' practices. Pediatrics2002;110(4):e42. [DOI: 10.1542/peds.110.4.e42] [PMID: 12359815]">Rubin 2002</a>). </p> <p>The most used first‐line treatment is a beta‐lactam antibiotic (most commonly ampicillin, flucloxacillin, or penicillin) combined with an aminoglycoside (most commonly gentamicin) (<a href="./references#CD013836-bbs2-0084" title="DongY , SpeerCP . Late-onset neonatal sepsis: recent developments. Archives of Disease in Childhood. Fetal and Neonatal Edition2015;100(3):F257-63. [DOI: 10.1136/archdischild-2014-306213] [PMID: 25425653]">Dong 2015</a>; <a href="./references#CD013836-bbs2-0180" title="VergnanoS , MensonE , KenneaN , EmbletonN , RussellAB , WattsT , et al. Neonatal infections in England: the NeonIN surveillance network. Archives of Disease in Childhood. Fetal and Neonatal Edition2011;96(1):F9-14. [DOI: 10.1136/adc.2009.178798] [PMID: 20876594]">Vergnano 2011</a>). However, there has been an increased use of alternatives, such as vancomycin and cephalosporins, due to increased drug resistance among the most common pathogen (e.g. coagulase‐negative staphylococci) (<a href="./references#CD013836-bbs2-0084" title="DongY , SpeerCP . Late-onset neonatal sepsis: recent developments. Archives of Disease in Childhood. Fetal and Neonatal Edition2015;100(3):F257-63. [DOI: 10.1136/archdischild-2014-306213] [PMID: 25425653]">Dong 2015</a>; <a href="./references#CD013836-bbs2-0146" title="RubinLG , SánchezPJ , SiegelJ , LevineG , SaimanL , JarvisWR , Pediatric Prevention Network. Evaluation and treatment of neonates with suspected late onset sepsis: a survey of neonatologists' practices. Pediatrics2002;110(4):e42. [DOI: 10.1542/peds.110.4.e42] [PMID: 12359815]">Rubin 2002</a>). </p> <p>Most guidelines recommend a penicillin plus an aminoglycoside for all cases of neonatal sepsis (<a href="./references#CD013836-bbs2-0077" title="CorteseF , ScicchitanoP , GesualdoM , FilaninnoA , De GiorgiE , SchettiniF , et al. Early and late infections in newborns: where do we stand? A review. Pediatrics and Neonatology2016;57(4):265-73. [DOI: 10.1016/j.pedneo.2015.09.007] [PMID: 26750406]">Cortese 2016</a>; <a href="./references#CD013836-bbs2-0125" title="MananMM , IbrahimNA , AzizNA , ZulkiflyHH , Al-WorafiYM , LongCM . Empirical use of antibiotic therapy in the prevention of early onset sepsis in neonates: a pilot study. Archives of Medical Science2016;12(3):603-13. [DOI: 10.5114/aoms.2015.51208] [PMID: 27279855]">Manan 2016</a>; <a href="./references#CD013836-bbs2-0138" title="Muller-PebodyB , JohnsonAP , HeathPT , GilbertRE , HendersonKL , SharlandM , iCAP Group. Empirical treatment of neonatal sepsis: are the current guidelines adequate?Archives of Disease in Childhood. Fetal and Neonatal Edition2011;96(1):F4-8. [DOI: 10.1136/adc.2009.178483] [PMID: 20584804]">Muller‐Pebody 2011</a>; <a href="./references#CD013836-bbs2-0179" title="VergnanoS , SharlandM , KazembeP , MwansamboC , HeathPT . Neonatal sepsis: an international perspective. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90(3):F220-4. [DOI: 10.1136/adc.2002.022863] [PMID: 15846011]">Vergnano 2005</a>; <a href="./references#CD013836-bbs2-0180" title="VergnanoS , MensonE , KenneaN , EmbletonN , RussellAB , WattsT , et al. Neonatal infections in England: the NeonIN surveillance network. Archives of Disease in Childhood. Fetal and Neonatal Edition2011;96(1):F9-14. [DOI: 10.1136/adc.2009.178798] [PMID: 20876594]">Vergnano 2011</a>; <a href="./references#CD013836-bbs2-0192" title="World Health Organization. Pocket book of hospital care for children: second edition. Guidelines for the management of common childhood illnesses. apps.who.int/iris/bitstream/10665/81170/1/9789241548373_eng.pdf?ua=1 (accessed 16 February 2018).">WHO 2013</a>). However, other protocols exist where a cephalosporin or a glycopeptide is used as a first‐line option to treat late‐onset sepsis (<a href="./references#CD013836-bbs2-0086" title="FernandoAM , HeathPT , MensonEN . Antimicrobial policies in the neonatal units of the United Kingdom and Republic of Ireland. Journal of Antimicrobial Chemotherapy2008;61(3):743-5. [DOI: 10.1093/jac/dkm543] [PMID: 18238883]">Fernando 2008</a>; <a href="./references#CD013836-bbs2-0126" title="MarchantEA , BoyceGK , SadaranganiM , LavoiePM . Neonatal sepsis due to coagulase-negative Staphylococci. Clinical &amp; Developmental Immunology2013;2013:586076. [DOI: 10.1155/2013/586076] [PMID: 23762094]">Marchant 2013</a>; <a href="./references#CD013836-bbs2-0162" title="StockmannC , SpigarelliMG , CampbellSC , ConstanceJE , CourterJD , ThorellEA , et al. Considerations in the pharmacologic treatment and prevention of neonatal sepsis. Paediatric Drugs2014;16(1):67-81. [DOI: 10.1007/s40272-013-0057-x] [PMID: 24218112]">Stockmann 2014</a>). Guidelines may differ due to local antibiotic resistance of the most common pathogens or whether the empirical regimen is supposed to cover the common but low virulence coagulase‐negative staphylococci (<a href="./references#CD013836-bbs2-0066" title="BizzarroMJ , ShabanovaV , BaltimoreRS , DembryLM , EhrenkranzRA , GallagherPG . Neonatal sepsis 2004-2013: the rise and fall of coagulase-negative Staphylococci. Journal of Pediatrics2015;166(5):1193-9. [DOI: 10.1016/j.jpeds.2015.02.009] [PMID: 25919728]">Bizzarro 2015</a>; <a href="./references#CD013836-bbs2-0126" title="MarchantEA , BoyceGK , SadaranganiM , LavoiePM . Neonatal sepsis due to coagulase-negative Staphylococci. Clinical &amp; Developmental Immunology2013;2013:586076. [DOI: 10.1155/2013/586076] [PMID: 23762094]">Marchant 2013</a>). Vancomycin is to be considered if staphylococcal infection is suspected (<a href="./references#CD013836-bbs2-0162" title="StockmannC , SpigarelliMG , CampbellSC , ConstanceJE , CourterJD , ThorellEA , et al. Considerations in the pharmacologic treatment and prevention of neonatal sepsis. Paediatric Drugs2014;16(1):67-81. [DOI: 10.1007/s40272-013-0057-x] [PMID: 24218112]">Stockmann 2014</a>). </p> <section id="CD013836-sec-0015"> <h4 class="title">Antibiotic susceptibility</h4> <p>Antibiotic resistance is a growing problem that increases the morbidity, mortality, and costs associated with infections globally (<a href="./references#CD013836-bbs2-0075" title="CohenML . Epidemiology of drug resistance: implications for a post-antimicrobial era. Science1992;257(5073):1050-5. [DOI: 10.1126/science.257.5073.1050] [PMID: 1509255]">Cohen 1992</a>; <a href="./references#CD013836-bbs2-0089" title="FosterKR , GrundmannH . Do we need to put society first? The potential for tragedy in antimicrobial resistance. PLoS Medicine2006;3(2):e29. [DOI: 10.1371/journal.pmed.0030029] [PMID: 16398572]">Foster 2006</a>; <a href="./references#CD013836-bbs2-0103" title="HuynhBT , PadgetM , GarinB , Delarocque-AstagneauE , GuillemotD , BIRDY study group. Bacterial neonatal sepsis and antibiotic resistance in low-income countries. Lancet2016;387(10018):533-4. [DOI: 10.1016/S0140-6736(16)00220-8] [PMID: 26867442]">Huynh 2016</a>; <a href="./references#CD013836-bbs2-0179" title="VergnanoS , SharlandM , KazembeP , MwansamboC , HeathPT . Neonatal sepsis: an international perspective. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90(3):F220-4. [DOI: 10.1136/adc.2002.022863] [PMID: 15846011]">Vergnano 2005</a>). Studies indicate that bacterial resistance to antibiotics results primarily from the selective pressure exerted by the use and overuse of antibiotics (<a href="./references#CD013836-bbs2-0089" title="FosterKR , GrundmannH . Do we need to put society first? The potential for tragedy in antimicrobial resistance. PLoS Medicine2006;3(2):e29. [DOI: 10.1371/journal.pmed.0030029] [PMID: 16398572]">Foster 2006</a>; <a href="./references#CD013836-bbs2-0117" title="KuninCM , JohansenKS , WorningAM , DaschnerFD . Report of a symposium on use and abuse of antibiotics worldwide. Reviews of Infectious Diseases1990;12(1):12-9. [DOI: 10.1093/clinids/12.1.12] [PMID: 2405465]">Kunin 1990</a>; <a href="./references#CD013836-bbs2-0131" title="McGowan JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance?Infection Control and Hospital Epidemiology1994;15(7):478-83. [DOI: 10.1086/646954] [PMID: 7963440]">McGowan 1994</a>; <a href="./references#CD013836-bbs2-0139" title="MurrayBE . Can antibiotic resistance be controlled?New England Journal of Medicine1994;330(17):1229-30. [DOI: 10.1056/NEJM199404283301710] [PMID: 8139634]">Murray 1994</a>; <a href="./references#CD013836-bbs2-0148" title="Sáez-LlorensX , Castrejón de WongMM , CastañoE , De SumanO , De MorösD , De AtencioI . Impact of an antibiotic restriction policy on hospital expenditures and bacterial susceptibilities: a lesson from a pediatric institution in a developing country. Pediatric Infectious Disease Journal2000;19(3):200-6. [DOI: 10.1097/00006454-200003000-00005] [PMID: 10749459]">Sáez‐Llorens 2000</a>). The spread of drug‐resistant organisms in hospitals is a recognised problem, although neonates admitted from the community may also carry drug‐resistant pathogens (<a href="./references#CD013836-bbs2-0063" title="BhuttaZA . Enterobacter sepsis in the newborn – a growing problem in Karachi. Journal of Hospital Infection1996;34(3):211-6. [DOI: 10.1016/s0195-6701(96)90068-7] [PMID: 8923276]">Bhutta 1996</a>). Studies that compare antibiotic susceptibility over time in the same unit show increased resistance to the most used antibiotics (<a href="./references#CD013836-bbs2-0179" title="VergnanoS , SharlandM , KazembeP , MwansamboC , HeathPT . Neonatal sepsis: an international perspective. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90(3):F220-4. [DOI: 10.1136/adc.2002.022863] [PMID: 15846011]">Vergnano 2005</a>). </p> <p>The pathogens that cause neonatal infections and their antibiotic susceptibility patterns change over time and may differ between countries (<a href="./references#CD013836-bbs2-0068" title="BreurecS , BouchiatC , SireJM , MoquetO , BercionR , CisseMF , et al. High third-generation cephalosporin resistant Enterobacteriaceae prevalence rate among neonatal infections in Dakar, Senegal. BMC Infectious Diseases2016;16(1):587. [DOI: 10.1186/s12879-016-1935-y] [PMID: 27765017]">Breurec 2016</a>; <a href="./references#CD013836-bbs2-0108" title="IsaacsD , Australasian Study Group for Neonatal Infections. A ten year, multicentre study of coagulase negative staphylococcal infections in Australasian neonatal units. Archives of Disease in Childhood. Fetal and Neonatal Edition2003;88(2):F89-93. [DOI: 10.1136/fn.88.2.f89] [PMID: 12598493]">Isaacs 2003</a>; <a href="./references#CD013836-bbs2-0128" title="MayM , DaleyAJ , DonathS , IsaacsD , Australasian Study Group for Neonatal Infections. Early onset neonatal meningitis in Australia and New Zealand, 1992-2002. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90(4):F324-7. [DOI: 10.1136/adc.2004.066134] [PMID: 15878934 ]">May 2005</a>; <a href="./references#CD013836-bbs2-0165" title="StollBJ , HansenN . Infections in VLBW infants: studies from the NICHD Neonatal Research Network. Seminars in Perinatology2003;27(4):293-301. [DOI: 10.1016/s0146-0005(03)00046-6] [PMID: 14510320]">Stoll 2003</a>; <a href="./references#CD013836-bbs2-0166" title="StollBJ , HansenNI , HigginsRD , FanaroffAA , DuaraS , GoldbergR , et al, National Institute of Child Health and Human Development. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of Gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatric Infectious Disease Journal2005;24(7):635-9. [DOI: 10.1097/01.inf.0000168749.82105.64] [PMID: 15999007]">Stoll 2005</a>; <a href="./references#CD013836-bbs2-0180" title="VergnanoS , MensonE , KenneaN , EmbletonN , RussellAB , WattsT , et al. Neonatal infections in England: the NeonIN surveillance network. Archives of Disease in Childhood. Fetal and Neonatal Edition2011;96(1):F9-14. [DOI: 10.1136/adc.2009.178798] [PMID: 20876594]">Vergnano 2011</a>). Furthermore, the definition and epidemiology of neonatal sepsis differs between countries (<a href="./references#CD013836-bbs2-0179" title="VergnanoS , SharlandM , KazembeP , MwansamboC , HeathPT . Neonatal sepsis: an international perspective. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90(3):F220-4. [DOI: 10.1136/adc.2002.022863] [PMID: 15846011]">Vergnano 2005</a>). This makes the comparison of antibiotic susceptibility between countries difficult. When comparing the epidemiology of neonatal sepsis in LMICs with high‐income countries, some important differences emerge in the pattern of aetiological pathogens and their antibiotic resistance (<a href="./references#CD013836-bbs2-0114" title="KhatuaSP , DasAK , ChatterjeeBD , KhatuaS , GhoseB , SahaA . Neonatal septicemia. Indian Journal of Pediatrics1986;53(4):509-14. [DOI: 10.1007/BF02749537] [PMID: 3542818]">Khatua 1986</a>; <a href="./references#CD013836-bbs2-0170" title="TallurSS , KasturiAV , NadgirSD , KrishnaBV . Clinico-bacteriological study of neonatal septicemia in Hubli. Indian Journal of Pediatrics2000;67(3):169-74. [DOI: 10.1007/BF02723654] [PMID: 10838717]">Tallur 2000</a>; <a href="./references#CD013836-bbs2-0172" title="TessinI , TrollforsB , ThiringerK . Incidence and etiology of neonatal septicaemia and meningitis in western Sweden 1975-1986. Acta Paediatrica Scandinavica1990;79(11):1023-30. [DOI: 10.1111/j.1651-2227.1990.tb11378.x] [PMID: 2267918]">Tessin 1990</a>; <a href="./references#CD013836-bbs2-0181" title="VesikariT , JanasM , GrönroosP , TuppurainenN , RenlundM , KeroP , et al. Neonatal septicaemia. Archives of Disease in Childhood1985;60(6):542-6. [DOI: 10.1136/adc.60.6.542] [PMID: 3925895]">Vesikari 1985</a>). </p> <p>In high‐income countries, most pathogens that cause late‐onset sepsis (84%) were susceptible to the commonly used empiric antibiotics (penicillin/gentamicin and flucloxacillin/gentamicin) (<a href="./references#CD013836-bbs2-0180" title="VergnanoS , MensonE , KenneaN , EmbletonN , RussellAB , WattsT , et al. Neonatal infections in England: the NeonIN surveillance network. Archives of Disease in Childhood. Fetal and Neonatal Edition2011;96(1):F9-14. [DOI: 10.1136/adc.2009.178798] [PMID: 20876594]">Vergnano 2011</a>). </p> <p>In LMICs, estimations suggest that up to 70% of pathogens isolated from neonatal sepsis may not be covered by the recommended empirical regimen of ampicillin and gentamicin (<a href="./references#CD013836-bbs2-0197" title="ZaidiAK , HuskinsWC , ThaverD , BhuttaZA , AbbasZ , GoldmannDA . Hospital-acquired neonatal infections in developing countries. Lancet2005;365(9465):1175-88. [DOI: 10.1016/S0140-6736(05)71881-X] [PMID: 15794973]">Zaidi 2005</a>). Some studies in LMICs have shown almost universal resistance (92% to 100% resistance) among some of the most common pathogens to first‐ and second‐line antibiotics (<a href="./references#CD013836-bbs2-0081" title="DagnewM , YismawG , GizachewM , GadisaA , AbebeT , TadesseT , et al. Bacterial profile and antimicrobial susceptibility pattern in septicemia suspected patients attending Gondar University Hospital, Northwest Ethiopia. BMC Research Notes2013;6:283. [DOI: 10.1186/1756-0500-6-283] [PMID: 23875886]">Dagnew 2013</a>; <a href="./references#CD013836-bbs2-0111" title="KabweM , TemboJ , ChilukutuL , ChilufyaM , NgulubeF , LukwesaC , et al. Etiology, antibiotic resistance and risk factors for neonatal sepsis in a large referral center in Zambia. Pediatric Infectious Disease Journal2016;35(7):e191-8. [DOI: 10.1097/INF.0000000000001154] [PMID: 27031259]">Kabwe 2016</a>; <a href="./references#CD013836-bbs2-0197" title="ZaidiAK , HuskinsWC , ThaverD , BhuttaZA , AbbasZ , GoldmannDA . Hospital-acquired neonatal infections in developing countries. Lancet2005;365(9465):1175-88. [DOI: 10.1016/S0140-6736(05)71881-X] [PMID: 15794973]">Zaidi 2005</a>). </p> <p>In addition to antibiotic coverage, supportive care aiming to reverse the life‐threatening organ dysfunction caused by a dysregulated host response to infection is also part of the care for neonates with sepsis. This includes respiratory support, maintenance of peripheral perfusion (intravenous fluids and inotropics), phototherapy, temperature, and glucose regulation (<a href="./references#CD013836-bbs2-0153" title="SealeAC , ObieroCW , BerkleyJA . Rational development of guidelines for management of neonatal sepsis in developing countries. Current Opinion in Infectious Diseases2015;28(3):225-30. [DOI: 10.1097/QCO.0000000000000163] [PMID: 25887615]">Seale 2015</a>; <a href="./references#CD013836-bbs2-0192" title="World Health Organization. Pocket book of hospital care for children: second edition. Guidelines for the management of common childhood illnesses. apps.who.int/iris/bitstream/10665/81170/1/9789241548373_eng.pdf?ua=1 (accessed 16 February 2018).">WHO 2013</a>). </p> </section> <section id="CD013836-sec-0016"> <h4 class="title">Adverse events</h4> <p>Use of ampicillin has been associated in some studies with adverse events, such as rashes, diarrhoea, nausea, and nephrotoxicity (<a href="./references#CD013836-bbs2-0091" title="GolanDE , TashlianAH , ArmstrongEJ , ArmstrongAW . Principles of Pharmacology. 3rd edition. Philadelphia (PA): Lippincott Williams &amp; Wilkins, 2011.">Golan 2011</a>; <a href="./references#CD013836-bbs2-0113" title="KatzungBG , MastersSB , TrevorAJ . Basic and Clinical Pharmacology. 11th edition. New York (NY): McGraw-Hill Medical Publishing Division, 2009.">Katzung 2009</a>; <a href="./references#CD013836-bbs2-0137" title="MrvosR , PummerTL , KrenzelokEP . Amoxicillin renal toxicity: how often does it occur?Pediatric Emergency Care2013;29(5):641-3. [DOI: 10.1097/PEC.0b013e31828e9e78] [PMID: 23603656]">Mrvos 2013</a>). Contrary to these findings, one systematic review of randomised controlled trials (RCTs) showed that ampicillin only increased the incidence of candidiasis with no significant increase in rashes, diarrhoea, nausea, or nephrotoxicity (<a href="./references#CD013836-bbs2-0090" title="GilliesM , RanakusumaA , HoffmannT , ThorningS , McGuireT , GlasziouP , et al. Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication. Canadian Medical Association Journal2015;187(1):E21-31. [DOI: 10.1503/cmaj.140848] [PMID: 25404399]">Gillies 2015</a>). </p> <p>Aminoglycosides (e.g. gentamicin) have been shown to be toxic (nephrotoxicity and ototoxicity) in adults. However, their toxicity in neonates remains unclear (<a href="./references#CD013836-bbs2-0102" title="HuthME , RicciAJ , ChengAG . Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. International Journal of Otolaryngology2011;2011:937861. [DOI: 10.1155/2011/937861] [PMID: 22121370]">Huth 2011</a>; <a href="./references#CD013836-bbs2-0109" title="JacksonGG , ArcieriG . Ototoxicity of gentamicin in man: a survey and controlled analysis of clinical experience in the United States. Journal of Infectious Diseases1971;124(Suppl):S130-7. [DOI: 10.1093/infdis/124.supplement_1.s130] [PMID: 5126239]">Jackson 1971</a>; <a href="./references#CD013836-bbs2-0127" title="MattieH , CraigWA , PechèreJC . Determinants of efficacy and toxicity of aminoglycosides. Journal of Antimicrobial Chemotherapy1989;24(3):281-93. [DOI: 10.1093/jac/24.3.281] [PMID: 2681115]">Mattie 1989</a>; <a href="./references#CD013836-bbs2-0129" title="McGloneA , CranswickN . Evidence behind the WHO guidelines: hospital care for children: what is the evidence of safety of gentamicin use in children?Journal of Tropical Pediatrics2008;54(5):291-3. [DOI: 10.1093/tropej/fmn059] [PMID: 18710895]">McGlone 2008</a>; <a href="./references#CD013836-bbs2-0134" title="Mingeot-LeclercqMP , TulkensPM . Aminoglycosides: nephrotoxicity. Antimicrobial Agents and Chemotherapy1999;43(5):1003-12. [DOI: 10.1128/AAC.43.5.1003] [PMID: 10223907]">Mingeot‐Leclercq 1999</a>; <a href="./references#CD013836-bbs2-0140" title="MusiimeGM , SealeAC , MoxonSG , LawnJE . Risk of gentamicin toxicity in neonates treated for possible severe bacterial infection in low- and middle-income countries: systematic review. Tropical Medicine &amp; International Health2015;20(12):1593-606. [DOI: 10.1111/tmi.12608] [PMID: 26426298]">Musiime 2015</a>; <a href="./references#CD013836-bbs2-0151" title="SchultzeRG , WintersRE , KauffmanH . Possible nephrotoxicity of gentamicin. Journal of Infectious Diseases1971;124(Suppl):S145-7. [DOI: 10.1093/infdis/124.supplement_1.s145] [PMID: 5126240]">Schultze 1971</a>; <a href="./references#CD013836-bbs2-0154" title="SelimogluE . Aminoglycoside-induced ototoxicity. Current Pharmaceutical Design2007;13(1):119-26. [DOI: 10.2174/138161207779313731] [PMID: 17266591]">Selimoglu 2007</a>; <a href="./references#CD013836-bbs2-0185" title="WargoKA , EdwardsJD . Aminoglycoside-induced nephrotoxicity. Journal of Pharmacy Practice2014;27(6):573-7. [DOI: 10.1177/0897190014546836] [PMID: 25199523]">Wargo 2014</a>). </p> <p>The most common adverse effects caused by vancomycin are fever, phlebitis, and, in rare cases, nephrotoxicity and ototoxicity (<a href="./references#CD013836-bbs2-0147" title="RybakMJ , LomaestroBM , RotschaferJC , Moellering RC Jr, CraigWA , BilleterM , et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy2009;29(11):1275-9. [DOI: 10.1592/phco.29.11.1275] [PMID: 19873687]">Rybak 2009</a>). However, in addition to the development of resistance towards vancomycin, one must also consider that observational studies suggest a three‐ to four‐fold increase in nephrotoxicity when aminoglycosides are combined with vancomycin (<a href="./references#CD013836-bbs2-0085" title="FarberBF , Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrobial Agents and Chemotherapy1983;23(1):138-41. [DOI: 10.1128/aac.23.1.138] [PMID: 6219616]">Farber 1983</a>; <a href="./references#CD013836-bbs2-0095" title="HailemeskelB , NamannyM , WutohA . Frequency of nephrotoxicity with vancomycin and aminoglycoside antibiotic therapy. Hospital Pharmacy1999;34(12):1417-20. [DOI: 10.1177/194512539903401209]">Hailemeskel 1999</a>; <a href="./references#CD013836-bbs2-0147" title="RybakMJ , LomaestroBM , RotschaferJC , Moellering RC Jr, CraigWA , BilleterM , et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy2009;29(11):1275-9. [DOI: 10.1592/phco.29.11.1275] [PMID: 19873687]">Rybak 2009</a>; <a href="./references#CD013836-bbs2-0160" title="SorrellTC , CollignonPJ . A prospective study of adverse reactions associated with vancomycin therapy. Journal of Antimicrobial Chemotherapy1985;16(2):235-41. [DOI: 10.1093/jac/16.2.235] [PMID: 3934126]">Sorrell 1985</a>). </p> <p>Cefotaxime, which is considered an alternative first‐line antibiotic, might have a broad spectrum of activity. However, cefotaxime is also associated with increased risk of death and invasive candidiasis in non‐randomised studies (<a href="./references#CD013836-bbs2-0073" title="ClarkRH , BloomBT , SpitzerAR , GerstmannDR . Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics2006;117(1):67-74. [DOI: 10.1542/peds.2005-0179] [PMID: 16396862]">Clark 2006a</a>; <a href="./references#CD013836-bbs2-0078" title="CottenCM , McDonaldS , StollB , GoldbergRN , PooleK , Benjamin DK Jr, National Institute for Child Health and Human Development Neonatal Research Network. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics2006;118(2):717-22. [DOI: 10.1542/peds.2005-2677] [PMID: 16882828]">Cotten 2006</a>; <a href="./references#CD013836-bbs2-0162" title="StockmannC , SpigarelliMG , CampbellSC , ConstanceJE , CourterJD , ThorellEA , et al. Considerations in the pharmacologic treatment and prevention of neonatal sepsis. Paediatric Drugs2014;16(1):67-81. [DOI: 10.1007/s40272-013-0057-x] [PMID: 24218112]">Stockmann 2014</a>). </p> <p>In addition to the specific adverse effects of each antibiotic, extended use of antibiotics is also associated with higher risk of neonatal candidaemia (<a href="./references#CD013836-bbs2-0087" title="FiliotiJ , SpiroglouK , RoilidesE . Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Medicine2007;33(7):1272-83. [DOI: 10.1007/s00134-007-0672-5] [PMID: 17503015]">Filioti 2007</a>; <a href="./references#CD013836-bbs2-0161" title="SpiliopoulouA , DimitriouG , JelastopuluE , GiannakopoulosI , AnastassiouED , ChristofidouM . Neonatal intensive care unit candidemia: epidemiology, risk factors, outcome, and critical review of published case series. Mycopathologia2012;173(4):219-28. [DOI: 10.1007/s11046-011-9498-3] [PMID: 22076411]">Spiliopoulou 2012</a>). </p> </section> </section> <section id="CD013836-sec-0017"> <h3 class="title" id="CD013836-sec-0017">How the intervention might work</h3> <p>Antibiotics are antimicrobial drugs that treat and prevent bacterial infections by either killing or inhibiting the growth of the bacteria (<a href="./references#CD013836-bbs2-0183" title="WaksmanSA . What is an antibiotic or an antibiotic substance?Mycologia1947;39(5):565-9. [DOI: 10.1056/NEJM194712042372302.] [PMID: 20264541]">Waksman 1947</a>). They can be classified based on: </p> <p> <ul id="CD013836-list-0003"> <li> <p>their mechanism of action (bactericidal or bacteriostatic);</p> </li> <li> <p>bacterial spectrum (broad or narrow); and</p> </li> <li> <p>chemical structure (e.g. penicillins, macrolides, quinolones, tetracyclines, or aminoglycosides) (<a href="./references#CD013836-bbs2-0062" title="BérdyJ . Bioactive microbial metabolites. Journal of Antibiotics2005;58(1):1-26. [DOI: 10.1038/ja.2005.1] [PMID: 15813176]">Bérdy 2005</a>). </p> </li> </ul> </p> <p>A combination of different antibiotics might have several advantages. First, it is thought to provide an enhanced effect beyond the additive effects of the individual therapies (<a href="./references#CD013836-bbs2-0056" title="AllanJD , Moellering RC Jr. Management of infections caused by Gram-negative bacilli: the role of antimicrobial combinations. Review of Infectious Diseases1985;7(Suppl 4):S559-71. [DOI: 10.1093/clinids/7.supplement_4.s559] [PMID: 3909313]">Allan 1985</a>). Second, it can be used to broaden the spectrum of antibiotic coverage when used empirically to increase the chances of covering the alleged causative bacteria. Third, a combination therapy is thought to suppress the development of subpopulations of micro‐organisms resistant to antibiotics (<a href="./references#CD013836-bbs2-0056" title="AllanJD , Moellering RC Jr. Management of infections caused by Gram-negative bacilli: the role of antimicrobial combinations. Review of Infectious Diseases1985;7(Suppl 4):S559-71. [DOI: 10.1093/clinids/7.supplement_4.s559] [PMID: 3909313]">Allan 1985</a>; <a href="./references#CD013836-bbs2-0133" title="MilatovicD , BravenyI . Development of resistance during antibiotic therapy. European Journal of Clinical Microbiology1987;6(3):234-44. [DOI: 10.1007/BF02017607] [PMID: 3305004]">Milatovic 1987</a>; <a href="./references#CD013836-bbs2-0171" title="TammaPD , CosgroveSE , MaragakisLL . Combination therapy for treatment of infections with Gram-negative bacteria. Clinical Microbiology Reviews2012;25(3):450-70. [DOI: 10.1128/CMR.05041-11] [PMID: 22763634]">Tamma 2012</a>). </p> </section> <section id="CD013836-sec-0018"> <h3 class="title" id="CD013836-sec-0018">Why it is important to do this review</h3> <p>Despite the high burden of neonatal sepsis, high‐quality evidence in diagnosis and treatment is scarce (<a href="./references#CD013836-bbs2-0199" title="Zea-VeraA , OchoaTJ . Challenges in the diagnosis and management of neonatal sepsis. Journal of Tropical Pediatrics2015;61(1):1-13. [DOI: 10.1093/tropej/fmu079] [PMID: 25604489]">Zea‐Vera 2015</a>). Yet, in adults, appropriate empirical antibiotic treatment halves the fatality associated with sepsis (<a href="./references#CD013836-bbs2-0104" title="IbrahimEH , ShermanG , WardS , FraserVJ , KollefMH . The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest2000;118(1):146-55. [DOI: 10.1378/chest.118.1.146] [PMID: 10893372]">Ibrahim 2000</a>; <a href="./references#CD013836-bbs2-0121" title="LeiboviciL , ShragaI , DruckerM , KonigsbergerH , SamraZ , PitlikSD . The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. Journal of Internal Medicine1998;244(5):379-86. [DOI: 10.1046/j.1365-2796.1998.00379.x] [PMID: 9845853]">Leibovici 1998</a>; <a href="./references#CD013836-bbs2-0143" title="PaulM , ShaniV , MuchtarE , KarivG , RobenshtokE , LeiboviciL . Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrobial Agents and Chemotherapy2010;54(11):4851-63. [DOI: 10.1128/AAC.00627-10] [PMID: 20733044]">Paul 2010</a>). Due to the diagnostic challenges of sepsis, and the relative immunosuppression of the newborn, many neonates receive antibiotics for suspected sepsis. In fact, antibiotics have become the most used therapeutics in NICUs (<a href="./references#CD013836-bbs2-0074" title="ClarkRH , BloomBT , SpitzerAR , GerstmannDR . Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics2006;117(6):1979-87. [DOI: 10.1542/peds.2005-1707] [PMID: 16740839]">Clark 2006b</a>). Studies suggest that up to 95% of newborns treated with antibiotics for suspected sepsis prove to have no evidence of infection (<a href="./references#CD013836-bbs2-0059" title="Bedford RussellAR , KumarR . Early onset neonatal sepsis: diagnostic dilemmas and practical management. Archives of Disease in Childhood. Fetal and Neonatal Edition2015;100(4):F350-4. [DOI: 10.1136/archdischild-2014-306193] [PMID: 25425652]">Bedford Russell 2015</a>; <a href="./references#CD013836-bbs2-0072" title="CanteyJ , WozniakPS , SánchezPJ . Prospective surveillance of antibiotic use in the neonatal intensive care unit: results from the SCOUT study. Pediatric Infectious Disease Journal2015;34(3):267-72. [DOI: 10.1097/INF.0000000000000542] [PMID: 25191849]">Cantey 2015</a>; <a href="./references#CD013836-bbs2-0124" title="LuckS , TornyM , d'AgapeyeffK , PittA , HeathP , BreathnachA , et al. Estimated early-onset group B streptococcal neonatal disease. Lancet2003;361(9373):1953-4. [DOI: 10.1016/S0140-6736(03)13553-2] [PMID: 12801740]">Luck 2003</a>). This presumed inappropriate use of antibiotics seems to contribute to the development and spread of resistant pathogens in NICUs, and seems to be associated with adverse events (e.g. invasive candidiasis and increased antimicrobial resistance) (<a href="./references#CD013836-bbs2-0073" title="ClarkRH , BloomBT , SpitzerAR , GerstmannDR . Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics2006;117(1):67-74. [DOI: 10.1542/peds.2005-0179] [PMID: 16396862]">Clark 2006a</a>; <a href="./references#CD013836-bbs2-0076" title="CorderoL , AyersLW . Duration of empiric antibiotics for suspected early-onset sepsis in extremely low birth weight infants. Infection Control and Hospital Epidemiology2003;24(9):662-6. [DOI: 10.1086/502270] [PMID: 14510248]">Cordero 2003</a>; <a href="./references#CD013836-bbs2-0078" title="CottenCM , McDonaldS , StollB , GoldbergRN , PooleK , Benjamin DK Jr, National Institute for Child Health and Human Development Neonatal Research Network. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics2006;118(2):717-22. [DOI: 10.1542/peds.2005-2677] [PMID: 16882828]">Cotten 2006</a>; <a href="./references#CD013836-bbs2-0079" title="CottenCM , TaylorS , StollB , GoldbergRN , HansenNI , SánchezPJ , et al, NICHD Neonatal Research Network. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics2009;123(1):58-66. [DOI: 10.1542/peds.2007-3423] [PMID: 19117861]">Cotten 2009</a>; <a href="./references#CD013836-bbs2-0089" title="FosterKR , GrundmannH . Do we need to put society first? The potential for tragedy in antimicrobial resistance. PLoS Medicine2006;3(2):e29. [DOI: 10.1371/journal.pmed.0030029] [PMID: 16398572]">Foster 2006</a>; <a href="./references#CD013836-bbs2-0118" title="KuppalaVS , Meinzen-DerrJ , MorrowAL , SchiblerKR . Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. Journal of Pediatrics2011;159(5):720-5. [DOI: 10.1016/j.jpeds.2011.05.033] [PMID: 21784435]">Kuppala 2011</a>). </p> <p>The Cochrane Review published in 2005 concluded that there was inadequate evidence from RCTs in favour of any particular antibiotic regimen for the treatment of suspected late‐onset neonatal sepsis (<a href="./references#CD013836-bbs2-0093" title="GordonA , JefferyHE . Antibiotic regimens for suspected late onset sepsis in newborn infants. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD004501. [DOI: 10.1002/14651858.CD004501.pub2]">Gordon 2005</a>). No other systematic review has been conducted to date to assess the effects of different antibiotic regimens for suspected late‐onset sepsis. Therefore, there is a need for an updated systematic review that assesses the effects of different antibiotic regimens for late‐onset sepsis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013836-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013836-sec-0019"></div> <p>To assess the beneficial and harmful effects of different antibiotic regimens for late‐onset neonatal sepsis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013836-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013836-sec-0020"></div> <section id="CD013836-sec-0021"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013836-sec-0022"> <h4 class="title">Types of studies</h4> <p>We included RCTs, quasi‐RCTs, and cluster‐RCTs. We included trials regardless of publication type (e.g. full‐text or abstract), publication status (e.g. preprint or published), publication date, and language. We excluded crossover trials. </p> </section> <section id="CD013836-sec-0023"> <h4 class="title">Types of participants</h4> <p>We included participants suspected of or diagnosed with late‐onset sepsis (as defined by trial authors). </p> <p>We included participants if described as newborns or 72 hours of life or more (at randomisation), suspected or diagnosed with neonatal sepsis, meningitis, osteomyelitis, endocarditis, or NEC. </p> <p>We excluded trials that assessed treatment of fungal infections.</p> </section> <section id="CD013836-sec-0024"> <h4 class="title">Types of interventions</h4> <p>We accepted any type of antibiotic or combination of antibiotics, such as the following.</p> <p> <ul id="CD013836-list-0004"> <li> <p>Broad‐spectrum beta‐lactam antibiotics, defined as broad‐spectrum penicillins (e.g. ampicillin, amoxicillin, piperacillin, ticarcillin, carbenicillin, and mezlocillin), cephalosporins (e.g. cefazolin, cephalexin, cefuroxime, cefotetan, cefoxitin, ceftriaxone, cefotaxime, ceftazidime, cefepime, cefazolin, ceftobiprole, ceftolozane, and cefoperazone), carbapenems (e.g. imipenem, meropenem, doripenem, and ertapenem), and monobactams (e.g. aztreonam). Narrow‐spectrum antibiotics included narrow‐spectrum penicillins (e.g. oxacillin, cloxacillin, dicloxacillin, nafcillin, methicillin, and penicillin G). </p> </li> <li> <p>Beta‐lactam antibiotics with beta‐lactamase inhibitors such as avibactam, clavulanic acid, sulbactam, and tazobactam. </p> </li> <li> <p>Combination of beta‐lactam with aminoglycoside (e.g. gentamicin).</p> </li> <li> <p>Combination of beta‐lactam with glycopeptide (e.g. vancomycin and teicoplanin).</p> </li> <li> <p>Combination of glycopeptide with aminoglycoside.</p> </li> </ul> </p> <p>We planned to assess the following comparisons.</p> <p> <ul id="CD013836-list-0005"> <li> <p>Aminoglycoside added to any type of antibiotic versus any type of antibiotic (same antibiotic as in the experimental group). </p> </li> <li> <p>Broad‐spectrum beta‐lactam antibiotic and aminoglycoside versus narrow‐spectrum beta‐lactam antibiotic (as defined in the above) and aminoglycoside (same aminoglycoside as in the experimental group). </p> </li> <li> <p>Beta‐lactam antibiotic (as defined in the above) and aminoglycoside versus beta‐lactam antibiotic and glycopeptide. </p> </li> <li> <p>Any other used antibiotic regimen (not included in the above‐mentioned comparisons) versus any other used antibiotic regimen (not included in the above‐mentioned comparisons). </p> </li> </ul> </p> </section> <section id="CD013836-sec-0025"> <h4 class="title">Types of outcome measures</h4> <section id="CD013836-sec-0026"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013836-list-0006"> <li> <p>All‐cause mortality.</p> </li> </ul> </p> </section> <section id="CD013836-sec-0027"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013836-list-0007"> <li> <p>Proportion of participants with one or more serious adverse events. We defined a serious adverse event as any untoward medical occurrence that resulted in death, was life‐threatening, jeopardised the participant, was persistent, led to significant disability, hospitalisation, or prolonged hospitalisation (<a href="./references#CD013836-bbs2-0105" title="International Conference on Harmonisation-Good Clinical Practice. ICH harmonised guideline: integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2) ICH Consensus Guideline (ICH-GCP), 2015. ichgcp.net (accessed prior to 19 April 2021).">ICH‐GCP 2015</a>). As we expected the reporting of serious adverse events in many trials to be very heterogeneous and not strictly according to the recommendations regarding good clinical practice from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH‐GCP) (<a href="./references#CD013836-bbs2-0105" title="International Conference on Harmonisation-Good Clinical Practice. ICH harmonised guideline: integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2) ICH Consensus Guideline (ICH-GCP), 2015. ichgcp.net (accessed prior to 19 April 2021).">ICH‐GCP 2015</a>), we included the event as a serious adverse event if the trial authors either: used the term 'serious adverse event' but not refer to ICH‐GCP, or reported the proportion of participants with an event we consider fulfilled the ICH‐GCP definition (e.g. death or developed shock). If several such events were reported, we chose the highest proportion reported in each trial to avoid double‐counting. </p> </li> <li> <p>Respiratory support, defined as the need for respiratory support, such as non‐invasive ventilation (e.g. continuous positive airway pressure (CPAP)) or invasive ventilation (e.g. respirator). </p> </li> <li> <p>Circulatory support, defined as the need for circulatory support such as fluid bolus or vasoactive medication (e.g. inotropes or vasopressors). </p> </li> <li> <p>Nephrotoxicity measured as decreased urine output, decreased estimated creatine clearance, or increase in S‐creatinine according to guidelines (such as "Paediatric Risk, Injury, Failure, Loss, End‐Stage Kidney Disease (pRIFLE) system", "Acute Kidney Injury Network (AKIN) guideline", and "Kidney Disease: Improving Global Outcomes (KDIGO) guideline") (<a href="./references#CD013836-bbs2-0132" title="McWilliamSJ , AntoineDJ , SmythRL , PirmohamedM . Aminoglycoside-induced nephrotoxicity in children. Pediatric Nephrology2017;32(11):2015-25.">McWilliam 2017</a>) or as defined by the trial author. </p> </li> <li> <p>Presence of moderate‐to‐severe neurological developmental and sensory impairment (defined as a functional abnormality in the function of the brain, spinal cord, muscles, nerves, eyes, or ears, or as any significant lag in a child's physical or motor, cognitive, behavioural, emotional or social development, in comparison with other children of the same age and sex within similar environments. If formal evaluation tools were used to assess neurodevelopmental impairment, we planned to use a threshold of –2 standard deviations (SDs) of the normal. Furthermore, severe brain injury per se is included, such as intraventricular haemorrhage grade 3 and 4 (<a href="./references#CD013836-bbs2-0142" title="PapileLA , BursteinJ , BursteinR , KofflerH . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics1978;92(4):529-34. [DOI: 10.1016/s0022-3476(78)80282-0] [PMID: 305471]">Papile 1978</a>; <a href="./references#CD013836-bbs2-0182" title="VolpeJJ . Intracranial hemorrhage: germinal matrix intraventricular hemorrhage. In: Neurology of the Newborn. 5th edition. Philadelphia (PA): Saunders Elsevier, 2008:517-88.">Volpe 2008</a>), and periventricular leukomalacia. </p> </li> <li> <p>NEC during or after treatment, defined by Bell's criteria 2 (<a href="./references#CD013836-bbs2-0060" title="BellMJ , TernbergJL , FeiginRD , KeatingJP , MarshallR , BartonL , et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery1978;187(1):1-7. [DOI: 10.1097/00000658-197801000-00001] [PMID: 413500]">Bell 1978</a>) (participants with NEC at baseline were not included in the analysis of this outcome). </p> </li> <li> <p>Ototoxicity as defined by the trial authors.</p> </li> </ul> </p> <p>We assessed all dichotomised outcomes as proportions.</p> <p>We used the trial results reported at maximum follow‐up (our primary time point of interest). </p> </section> </section> </section> <section id="CD013836-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <p>We used the criteria and standard methods of Cochrane and Cochrane Neonatal (see the Cochrane Neonatal search strategy for Specialized Register; <a href="http://neonatal.cochrane.org/resources-review-authors" target="_blank">neonatal.cochrane.org/resources-review-authors</a>). We searched for errata or retractions from included studies published in full‐text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>). </p> <section id="CD013836-sec-0029"> <h4 class="title">Electronic searches</h4> <p>We conducted a comprehensive literature search including: the Cochrane Central Register of Controlled Trials (CENTRAL 2021, Issue 3) in the Cochrane Library; Ovid MEDLINE (1946 to 12 March 2021); Embase via Ovid (1974 to 12 March 2021); CINAHL (EBSCOhost; 12 March 2021); LILACS (Bireme; 1982 to 12 March 2021); and Science Citation Index EXPANDED and Conference Proceedings Citation Index – Science (1990 to 12 March 2021). We have included the search strategies for each database in <a href="./appendices#CD013836-sec-0136">Appendix 1</a>. </p> <p>We searched ZETOC for abstracts of scientific conferences or symposia (<a href="https://zetoc.jisc.ac.uk/" target="_blank">zetoc.jisc.ac.uk/</a>). </p> <p>We searched clinical trial registries for ongoing or recently completed trials. We searched the World Health Organization's International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>), and the U.S. National Library of Medicine's ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>), via Cochrane CENTRAL. Additionally, we searched the ISRCTN Registry for any unique trials not identified through the Cochrane CENTRAL search (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>). </p> <p>We applied no language restrictions. If we identified any papers in a language not known by the review author group, we sought translation assistance and acknowledged the translators in the <a href="#CD013836-sec-0133">Acknowledgements</a> section of the review. </p> </section> <section id="CD013836-sec-0030"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all relevant primary trials and reviews for additional references. </p> <p>To identify unpublished trials we also searched clinical trial registers of Europe and the USA, websites of pharmaceutical companies, and websites of the US Food and Drug Administration (FDA) and the European Medicines Agency. </p> </section> </section> <section id="CD013836-sec-0031"> <h3 class="title" id="CD013836-sec-0031">Data collection and analysis</h3> <section id="CD013836-sec-0032"> <h4 class="title">Selection of studies</h4> <p>Three review authors (SKK, CN, and SS) independently screened titles and abstracts. We retrieved all relevant full‐text study reports/publication and three review authors (SKK, CN, and SS) independently screened the full texts and identified trials for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreements through discussion or, if required, by consulting another review author (JCJ). We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD013836-bbs2-0135" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12. [DOI: 10.1016/j.jclinepi.2009.06.005] [PMID: 19631508]">Moher 2009</a>), and a <a href="./references#CD013836-sec-0161" title="">Characteristics of excluded studies</a> table. </p> <p>Where studies had multiple publications, we collated the reports of the same study so that each study, rather than each report, was the unit of interest for the review, and such studies had a single identifier with multiple references. </p> </section> <section id="CD013836-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>We used data collection forms for trial characteristics and outcome data that we piloted on at least one trial included in the review. Three review authors (SKK, CN, and SS) extracted trial characteristics from included trials. We extracted the following trials characteristics. </p> <p> <ul id="CD013836-list-0008"> <li> <p>Methods: trial design, total duration of the trial, number of trial centres and location, trial setting, withdrawals, and date of the trial. </p> </li> <li> <p>Participants: number of participants in each intervention group, mean age, age range, gender, diagnostic criteria, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention and comparison.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Three review authors (SKK, CN and SS) independently extracted outcome data from included trials. We noted in the <a href="./references#CD013836-sec-0160" title="">Characteristics of included studies</a> table if the trial authors did not report outcome data in a usable way. We resolved disagreements by consensus or by involving another review author (JCJ). One review author (SKK) transferred data into the Review Manager 5 (<a href="./references#CD013836-bbs2-0144" title="The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (SS) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD013836-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SKK and SS) independently assessed the risk of bias (low, high, or unclear) of all included trials using the Cochrane 'Risk of bias' tool for the following domains (<a href="./references#CD013836-bbs2-0099" title="HigginsJP , AltmanDG , Sterne JA: on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p> <ul id="CD013836-list-0009"> <li> <p>Sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Any other bias.</p> </li> </ul> </p> <p>We resolved any disagreements by discussion or by consulting a third review author (JCJ). See <a href="./appendices#CD013836-sec-0143">Appendix 2</a> for a more detailed description of risk of bias for each domain. </p> <section id="CD013836-sec-0035"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol (<a href="./references#CD013836-bbs2-0201" title="KorangSK , SafiS , GuptaM , GreisenG , Lausten-ThomsenU , JakobsenJC . Antibiotic regimens for late-onset neonatal sepsis. Cochrane Database of Systematic Reviews2021, Issue 1. Art. No: CD013836. [DOI: 10.1002/14651858.CD013836]">Korang 2021</a>), and reported any deviations from it in the <a href="#CD013836-sec-0158">Differences between protocol and review</a> section. </p> </section> </section> <section id="CD013836-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <section id="CD013836-sec-0037"> <h5 class="title">Dichotomous outcomes</h5> <p>We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes. </p> </section> </section> <section id="CD013836-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participating infant in individually randomised trials and the neonatal unit (or subunit) for cluster‐RCTs. For cluster‐RCTs, we planned to undertake analyses at the level of the individual while accounting for the clustering in the data using the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013836-bbs2-0100" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> </section> <section id="CD013836-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We did not impute missing values for any outcomes in our primary analysis. In two of our sensitivity analyses, we planned to impute data (see <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012067/full#CD012067-sec3-0017" target="_blank">Sensitivity analysis</a>). </p> <p>We contacted investigators and trial sponsors to verify key trial characteristics and obtain missing numerical outcome data when possible (e.g. when we identified a study as an abstract only). </p> </section> <section id="CD013836-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to visually inspect forest plots to assess signs of heterogeneity, and we planned to explore possible heterogeneity in our prespecified subgroup analyses. We inspected trial characteristics across trials to identify clinical heterogeneity. We assessed the presence of statistical heterogeneity using the Chi² test (threshold P &lt; 0.10) and measured the quantities of heterogeneity using the I² statistic (<a href="./references#CD013836-bbs2-0097" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58. [DOI: 10.1002/sim.1186] [PMID: 12111919]">Higgins 2002</a>; <a href="./references#CD013836-bbs2-0098" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557] [PMID: 12958120]">Higgins 2003</a>). If we had detected moderate or high heterogeneity (I² statistic of 50% or greater), we planned to explore the possible causes (e.g. differences in study design, participants, interventions, or completeness of outcome assessments). </p> </section> <section id="CD013836-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use a funnel plot to assess publication bias if 10 or more trials met the inclusion criteria. We also planned to visually inspect funnel plots to assess the risk of bias. As we planned to report results when we analysed dichotomous outcomes using RRs, we did not use any tests to assess funnel plot asymmetry when analysing dichotomous outcomes (<a href="./references#CD013836-bbs2-0100" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> </section> <section id="CD013836-sec-0042"> <h4 class="title">Data synthesis</h4> <section id="CD013836-sec-0043"> <h5 class="title">Meta‐analysis</h5> <p>We planned to undertake this meta‐analysis according to the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013836-bbs2-0100" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). We planned to use Review Manager 5 to analyse data (<a href="./references#CD013836-bbs2-0144" title="The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <p>We planned to assess our intervention effects using fixed‐effect meta‐analyses (<a href="./references#CD013836-bbs2-0082" title="DemetsDL . Methods of combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341-50. [DOI: 10.1002/sim.4780060325] [PMID: 3616287]">Demets 1987</a>), in accordance with the policies of Cochrane Neonatal. We used one primary outcome and, therefore, we considered a P value of 0.05 or less as the threshold for statistical significance (<a href="./references#CD013836-bbs2-0110" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014</a>). We used the eight‐step procedure to assess if the thresholds for significance were crossed (<a href="./references#CD013836-bbs2-0110" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014</a>). Where data were only available from one trial, we planned to use Fisher's exact test for dichotomous data (<a href="./references#CD013836-bbs2-0088" title="FisherRA . On the interpretation of χ2 from contingency tables, and the calculation of P. Journal of the Royal Statistical Society1922;85(1):87-94. [DOI: 10.2307/2340521]">Fisher 1922</a>). </p> <p>Where a trial reported multiple trial arms, we planned to include only the relevant trial arms. If two comparisons were combined in the same meta‐analysis, we would halve the control group to avoid double‐counting. </p> </section> <section id="CD013836-sec-0044"> <h5 class="title">Trial sequential analysis</h5> <p>Traditional meta‐analysis runs the risk of random errors due to sparse data and repetitive testing of accumulating data when updating reviews. Therefore, we planned to perform trial sequential analysis (TSA) on the outcomes, to calculate the required information size and the cumulative Z‐curve's breach of relevant trial sequential monitoring boundaries (<a href="./references#CD013836-bbs2-0069" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology2008;61(8):763-9. [DOI: 10.1016/j.jclinepi.2007.10.007] [PMID: 18411040]">Brok 2008</a>; <a href="./references#CD013836-bbs2-0070" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta-analyses may be inconclusive – trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology2009;38(1):287-98. [DOI: 10.1093/ije/dyn188] [PMID: 18824466]">Brok 2009</a>; <a href="./references#CD013836-bbs2-0173" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?International Journal of Epidemiology2009;38(1):276-86. [DOI: 10.1093/ije/dyn179] [PMID: 18824467]">Thorlund 2009</a>; <a href="./references#CD013836-bbs2-0174" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf (accessed 7 January 2015).">Thorlund 2011</a>; <a href="./references#CD013836-bbs2-0177" title="Copenhagen Trial Unit. TSA – Trial Sequential Analysis, 2011. ctu.dk/tsa/ (accessed 7 January 2015).">TSA 2011</a>; <a href="./references#CD013836-bbs2-0188" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [DOI: 10.1016/j.jclinepi.2007.03.013] [PMID: 18083463]">Wetterslev 2008</a>; <a href="./references#CD013836-bbs2-0189" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86. [DOI: 10.1186/1471-2288-9-86] [PMID: 20042080]">Wetterslev 2009</a>; <a href="./references#CD013836-bbs2-0190" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39. [DOI: 10.1186/s12874-017-0315-7] [PMID: 28264661]">Wetterslev 2017</a>). We wished to control the risks of type I errors and type II errors. A more detailed description of TSA can be found at <a href="http://www.ctu.dk/tsa/" target="_blank">www.ctu.dk/tsa/</a>. We planned to assess our TSA intervention effects with both a random‐effects model (<a href="./references#CD013836-bbs2-0083" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88. [DOI: 10.1016/0197-2456(86)90046-2] [PMID: 3802833]">DerSimonian 1986</a>), and a fixed‐effect model (<a href="./references#CD013836-bbs2-0082" title="DemetsDL . Methods of combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341-50. [DOI: 10.1002/sim.4780060325] [PMID: 3616287]">Demets 1987</a>). </p> <p>For dichotomous outcomes, we planned to estimate the required information size based on the observed, unweighted proportion of participants with an outcome in the control group (the cumulative proportion of participants with an event in the control groups relative to all participants in the control groups), a relative risk reduction of 20%, an alpha of 5%, a beta of 20%, and diversity as suggested by the trials in the meta‐analysis. </p> </section> </section> <section id="CD013836-sec-0045"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroup analyses for our primary outcome.</p> <p> <ul id="CD013836-list-0010"> <li> <p>High risk of bias trials compared with low risk of bias trials.</p> </li> <li> <p>Gestational age: term (37 weeks or greater) compared with preterm.</p> </li> <li> <p>Trials from high‐income countries compared with trials from LMICs, as defined by the World Bank (<a href="./references#CD013836-bbs2-0193" title="World Bank. World Bank country and lending groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 9 December 2019).">World Bank 2017</a>). </p> </li> <li> <p>Late‐onset sepsis defined by: onset after 48 hours, after 72 hours, after one week, or as defined by the trial authors. </p> </li> <li> <p>Clinically suspected sepsis compared with culture‐supported suspicion of severe bacterial infection. </p> </li> <li> <p>Trials including participants with coagulase‐negative staphylococci versus trials excluding participants with coagulase‐negative staphylococci. </p> </li> </ul> </p> <p>We planned to use the formal test for subgroup interactions in Review Manager 5 (<a href="./references#CD013836-bbs2-0144" title="The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We did not perform any of the above subgroups due to a lack of data. </p> </section> <section id="CD013836-sec-0046"> <h4 class="title">Sensitivity analysis</h4> <p>To assess the potential impact of the missing data, we planned to perform the two following sensitivity analyses on the primary outcome and the secondary outcome serious adverse events. </p> <p> <ul id="CD013836-list-0011"> <li> <p>'Best‐worst‐case' scenario: we planned to assume that all participants lost to follow‐up in the experimental group had survived and had no serious adverse event; and all those participants with missing outcomes in the control group had not survived and had a serious adverse event. </p> </li> <li> <p>'Worst‐best‐case' scenario: we planned to assume that all participants lost to follow‐up in the experimental group had not survived and had a serious adverse event; and that all those participants lost to follow‐up in the control group had survived and had no serious adverse event. </p> </li> </ul> </p> <p>We planned to present results of both scenarios in our review, but we did not perform any of the sensitivity analyses due to a lack of data. </p> </section> <section id="CD013836-sec-0047"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD013836-bbs2-0152" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>), to assess the certainty of evidence of the following (clinically relevant) outcomes: all‐cause mortality (primary outcome), and five secondary outcomes (serious adverse events, circulatory failure, nephrotoxicity, neurological developmental impairment, and NEC) at maximum follow‐up. </p> <p>Three review authors (SKK, SS, and CN) independently assessed the certainty of the evidence for each of the outcomes above. We considered evidence from RCTs as high certainty but downgraded the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates, and presence of publication bias. We used <a href="./references#CD013836-bbs2-0094" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 13 December 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a> to create five 'Summary of findings' tables to report the certainty of the evidence. </p> <p>The GRADE approach results in an assessment of the certainty of a body of evidence as one of four grades. </p> <p> <ul id="CD013836-list-0012"> <li> <p>High certainty: further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low certainty: we are very uncertain about the estimate.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013836-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013836-sec-0048"></div> <section id="CD013836-sec-0049"> <h3 class="title">Description of studies</h3> <p>We assessed all studies according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013836-bbs2-0100" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>), and the protocol for this review (<a href="./references#CD013836-bbs2-0201" title="KorangSK , SafiS , GuptaM , GreisenG , Lausten-ThomsenU , JakobsenJC . Antibiotic regimens for late-onset neonatal sepsis. Cochrane Database of Systematic Reviews2021, Issue 1. Art. No: CD013836. [DOI: 10.1002/14651858.CD013836]">Korang 2021</a>). Characteristics of each study can be found in the <a href="./references#CD013836-sec-0160" title="">Characteristics of included studies</a> and <a href="./references#CD013836-sec-0161" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD013836-sec-0050"> <h4 class="title">Results of the search</h4> <p>Our initial search identified 3356 references. We deemed 55 studies relevant and obtained full texts for further evaluation (see <a href="#CD013836-fig-0001">Figure 1</a>). Of these, we included five trials (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>; <a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>; <a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>; <a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>; <a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). We identified no ongoing trials relevant to the review. </p> <div class="figure" id="CD013836-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013836-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013836-sec-0051"> <h4 class="title">Included studies</h4> <p>Five trials met our inclusion criteria (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>; <a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>; <a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>; <a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>; <a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). For detailed descriptions, see the <a href="./references#CD013836-sec-0160" title="">Characteristics of included studies</a> table. Four of the trials were single centre, and one was multicentre. </p> <section id="CD013836-sec-0052"> <h5 class="title">Participants</h5> <p>The five trials included 580 participants. The mean proportion of girls was 46% among the trials that reported gender. </p> </section> <section id="CD013836-sec-0053"> <h5 class="title">Interventions</h5> <p>The trials reported five different antibiotic regimens.</p> <p> <ul id="CD013836-list-0013"> <li> <p>One trial assessed cefazolin plus amikacin compared with vancomycin plus amikacin (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>). </p> </li> <li> <p>One trial assessed ticarcillin plus clavulanic acid compared with flucloxacillin plus gentamicin (<a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>). </p> </li> <li> <p>One trial assessed cloxacillin plus amikacin compared with cefotaxime plus gentamicin (<a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). </p> </li> <li> <p>One trial assessed meropenem compared with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin) (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>). </p> </li> <li> <p>One trial assessed vancomycin plus gentamicin compared with vancomycin plus aztreonam (<a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>). </p> </li> </ul> </p> </section> <section id="CD013836-sec-0054"> <h5 class="title">Co‐interventions</h5> <p>Participants in all five trials received standard care in addition to the allocated antibiotic regimen. </p> </section> <section id="CD013836-sec-0055"> <h5 class="title">Outcomes</h5> <p>All five included trials reported all‐cause mortality and serious adverse events. None of the trials reported serious adverse events according to the ICH‐GCP, neither did they report serious adverse events as a composite outcome. Therefore, we reported the proportion of participants with an event we considered fulfilled the ICH‐GCP definition (e.g. shock or death). As there were several such events, we chose the highest proportion reported in each trial to avoid double‐counting. One trial reported circulatory support (<a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>), neurological developmental impairment (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>), and nephrotoxicity (<a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). Two trials reported NEC (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>; <a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>). None of the trials reported respiratory support or ototoxicity. </p> <section id="CD013836-sec-0056"> <h6 class="title">Antibiotic resistance in included trials</h6> <p>One trial (from different countries in Europe) reported 31 cases of resistance (towards meropenem) out of the 63 participants with positive cultures in the meropenem group, compared with 45 cases of resistance (towards one of the allocated antibiotics) out of the 75 participants with positive cultures in the standard care group (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>). </p> <p>One trial (from England) reported one case of resistance (towards gentamicin) out of the four participants with positive cultures in the flucloxacillin plus gentamicin group, but there was no resistance among the five participants with positive cultures in the ticarcillin plus clavulanic acid group (<a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>). </p> <p>The remaining three trials (from Argentina, England, and India) did not report resistance among the included participants towards the allocated antibiotics (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>; <a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>; <a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). </p> </section> </section> </section> <section id="CD013836-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We assessed 50 trials as relevant upon review of the abstract, but later excluded them upon review of the full publication. </p> <p> <ul id="CD013836-list-0014"> <li> <p>We excluded 24 trials because they were a mix of early‐ and late‐onset neonatal sepsis (<a href="./references#CD013836-bbs2-0006" title="AdelmanRD , WirthF , RubioT . A controlled study of the nephrotoxicity of mezlocillin and gentamicin plus ampicillin in the neonate. Journal of Pediatrics1987;111(6 Pt 1):888-93. [DOI: 10.1016/s0022-3476(87)80212-3] [PMID: 3316564]">Adelman 1987a</a>; <a href="./references#CD013836-bbs2-0007" title="AdelmanRD , WirthF , RubioT . A controlled study of the nephrotoxicity of mezlocillin and amikacin in the neonate. American Journal of Diseases of Children1987;141(11):1175-8. [DOI: 10.1001/archpedi.1987.04460110045019] [PMID: 3314475]">Adelman 1987b</a>; <a href="./references#CD013836-bbs2-0011" title="BaquiAH , SahaSK , AhmedA , ShahidullahM , QuasemI , RothDE , et al. Safety and efficacy of simplified antibiotic regimens for outpatient treatment of serious infection in neonates and young infants 0-59 days of age in Bangladesh: design of a randomized controlled trial. Pediatric Infectious Disease Journal2013;32(Suppl 1):S12-8. [DOI: 10.1097/INF.0b013e31829ff790] [PMID: 23945570]">Baqui 2013</a>; <a href="./references#CD013836-bbs2-0013" title="BegueP , AstrucJ , FrancoisP , FloretD . Comparison of ceftriaxone and cefotaxime in severe pediatric bacterial infections: a multicentrique study [Evaluation de la ceftriaxone et du cefotaxime dans l'infection bacterienne severe en pediatrie: etude multicentrique]. Medecine et Maladies Infectieuses1998;28(4):300-6. [DOI: 10.1016/S0399-077X(98)80054-1]">Begue 1998</a>; <a href="./references#CD013836-bbs2-0017" title="De LouvoisJ , DaganR , TessinI . A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in 1316 cases of suspected sepsis in the newborn. European Society for Paediatric Infectious Diseases – Neonatal Sepsis Study Group. European Journal of Pediatrics1992;151(12):876-84. [DOI: 10.1007/BF01954122] [PMID: 1473540]">De Louvois 1992</a>; <a href="./references#CD013836-bbs2-0020" title="FaixRG , PolleyTZ , GraselaTH . A randomized, controlled trial of parenteral clindamycin in neonatal necrotizing enterocolitis. Journal of Pediatrics1988;112(2):271-7. [DOI: 10.1016/s0022-3476(88)80069-6] [PMID: 3276864]">Faix 1988</a>; <a href="./references#CD013836-bbs2-0022" title="FogelD , FarfelL , MiskinA , MogilnerBM . Comparison between the combination of azlocillin-gentamicin and ampicillin-gentamicin in the treatment of a nursery population. Israel Journal of Medical Sciences1983;19(11):1009-15. [PMID: 6662683]">Fogel 1983</a>; <a href="./references#CD013836-bbs2-0024" title="GokalpAS , OguzA , GultekinA , IcagasiogluD . Neonatal sepsis in Turkey: the comparison between penicillin plus aminoglycoside and ampicillin plus third-generation cephalosporin chemotherapies. Materia Medica Polona. Polish Journal of Medicine and Pharmacy1991;23(3):226-28. [DOI: 10.1093/tropej/36.4.200] [PMID: 1842721]">Gokalp 1991</a>; <a href="./references#CD013836-bbs2-0025" title="HaffejeeIE . A therapeutic trial of cefotaxime versus penicillin-gentamicin for severe infections in children. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):147-52. [DOI: 10.1093/jac/14.suppl_b.147] [PMID: 6094434]">Haffejee 1984</a>; <a href="./references#CD013836-bbs2-0026" title="HallMA , DuckerDA , LowesJA , McMichaelJ , ClarkeP , RoweD , et al. A randomised prospective comparison of cefotaxime versus netilmicin/penicillin for treatment of suspected neonatal sepsis. Drugs1988;35(Suppl 2):169-77. ">Hall 1988</a>; <a href="./references#CD013836-bbs2-0032" title="LeeSJ , ParkEA . Efficacy and safety of amoxicillin-sulbactam and ampicillin-sulbactam in full term neonates. Journal of the Korean Society of Neonatology2005;12(1):17-24. ">Lee 2005</a>; <a href="./references#CD013836-bbs2-0034" title="MarksS , MarksMI , DupontC , HammerbergS . Evaluation of three antibiotic programs in newborn infants. Canadian Medical Association Journal1978;118(6):659-62. [PMID: 657058]">Marks 1978</a>; <a href="./references#CD013836-bbs2-0037" title="MirF , NisarI , TikmaniSS , BalochB , ShakoorS , JehanF , et al. Simplified antibiotic regimens for treatment of clinical severe infection in the outpatient setting when referral is not possible for young infants in Pakistan (Simplified Antibiotic Therapy Trial [SATT]): a randomised, open-label, equivalence trial. Lancet. Global Health2017;5(2):e177-85. [DOI: 10.1016/S2214-109X(16)30335-7] [PMID: 27988146]">Mir 2017</a>; <a href="./references#CD013836-bbs2-0038" title="MolyneuxEM , DubeQ , BandaFM , ChiumeM , SinginiI , MallewaM , et al. The treatment of possible severe infection in infants: an open randomized safety trial of parenteral benzylpenicillin and gentamicin versus ceftriaxone in Infants &lt;60 days of age in Malawi. Pediatric Infectious Disease Journal2017;36(12):e328-33. [DOI: 10.1097/INF.0000000000001576] [PMID: 28263245]">Molyneux 2017</a>; <a href="./references#CD013836-bbs2-0040" title="OdioCM , UmanaMA , SaenzA , SalasJL , McCracken GH Jr. Comparative efficacy of ceftazidime vs carbenicillin and amikacin for treatment of neonatal septicemia. Pediatric Infectious Disease Journal1987;6(4):371-7. [DOI: 10.1097/00006454-198704000-00006] [PMID: 3295738]">Odio 1987</a>; <a href="./references#CD013836-bbs2-0041" title="OdioCM . Cefotaxime for treatment of neonatal sepsis and meningitis. Diagnostic Microbiology and Infectious Disease1995;22(1-2):111-7. [DOI: 10.1016/0732-8893(95)00093-p] [PMID: 7587023]">Odio 1995</a>; <a href="./references#CD013836-bbs2-0045" title="TaheriPA , EslamiehH , SalamatiP . Is ceftizoxime an appropriate surrogate for amikacin in neonatal sepsis treatment? A randomized clinical trial. Acta Medica Iranica2011;49(8):499-503. [PMID: 22009803]">Taheri 2011</a>; <a href="./references#CD013836-bbs2-0046" title="TessinI , ThiringerK , TrollforsB , BrorsonJE . Comparison of serum concentrations of ceftazidime and tobramycin in newborn infants. European Journal of Pediatrics1988;147(4):405-7. [DOI: 10.1007/BF00496420] [PMID: 3294015]">Tessin 1988</a>; <a href="./references#CD013836-bbs2-0047" title="TessinI , TrollforsB , ThiringerK , ThörnZ , LarssonP . Concentrations of ceftazidime, tobramycin and ampicillin in the cerebrospinal fluid of newborn infants. European Journal of Pediatrics1989;148(7):679-81. [DOI: 10.1007/BF00441533] [PMID: 2663518]">Tessin 1989</a>; <a href="./references#CD013836-bbs2-0049" title="African Neonatal Sepsis Trial (AFRINEST) group, TshefuA , LokangakaA , NgaimaS , EngmannC , EsamaiF , GisoreP , et al. Simplified antibiotic regimens compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised, open-label, equivalence trial. Lancet2015;385(9979):1767-76. [DOI: 10.1016/S0140-6736(14)62284-4] [PMID: 25842221]">Tshefu 2015a</a>; <a href="./references#CD013836-bbs2-0050" title="African Neonatal Sepsis Trial (AFRINEST) group, TshefuA , LokangakaA , NgaimaS , EngmannC , EsamaiF , GisoreP , et al. Oral amoxicillin compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with fast breathing when referral is not possible: a randomised, open-label, equivalence trial. Lancet2015;385(9979):1758-66. [DOI: 10.1016/S0140-6736(14)62285-6] [PMID: 25842223]">Tshefu 2015b</a>; <a href="./references#CD013836-bbs2-0051" title="UmañaMA , OdioCM , CastroE , SalasJL , McCracken GH Jr. Evaluation of aztreonam and ampicillin vs amikacin and ampicillin for treatment of neonatal bacterial infections. Pediatrics Infectious Disease Journal1990;9(3):175-80. [DOI: 10.1097/00006454-199003000-00006] [PMID: 2186351]">Umaña 1990</a>; <a href="./references#CD013836-bbs2-0054" title="WieseG . Treatment of neonatal sepsis with ceftriaxone/gentamicin and with azlocillin/gentamicin: a clinical comparison of efficacy and tolerability. Chemotherapy1988;34(2):158-63. [DOI: 10.1159/000238564] [PMID: 3391053]">Wiese 1988</a>; <a href="./references#CD013836-bbs2-0055" title="ZaidiAK , TikmaniSS , SultanaS , BalochB , KaziM , RehmanH , et al. Simplified antibiotic regimens for the management of clinically diagnosed severe infections in newborns and young infants in first-level facilities in Karachi, Pakistan: study design for an outpatient randomized controlled equivalence trial. Pediatric Infectious Disease Journal2013;32(Suppl 1):S19-25. [DOI: 10.1097/INF.0b013e31829ff7aa] [PMID: 23945571]">Zaidi 2013</a>). </p> </li> <li> <p>In eight trials both groups received the same antibiotics (<a href="./references#CD013836-bbs2-0010" title="AuritiC , RavaL , Di CiommoV , RonchettiMP , OrzalesiM . Short antibiotic prophylaxis for bacterial infections in a neonatal intensive care unit: a randomized controlled trial. Journal of Hospital Infection2005;59(4):292-8. [DOI: 10.1016/j.jhin.2004.09.005] [PMID: 15749316]">Auriti 2005</a>; <a href="./references#CD013836-bbs2-0015" title="ChowdharyG , DuttaS , NarangA . Randomized controlled trial of 7-day vs. 14-day antibiotics for neonatal sepsis. Journal of Tropical Pediatrics2006;52(6):427-32. [DOI: 10.1093/tropej/fml054] [PMID: 17030532]">Chowdhary 2006</a>; <a href="./references#CD013836-bbs2-0023" title="GathwalaG , SindwaniA , SinghJ , ChoudhryO , ChaudharyU . Ten days vs. 14 days antibiotic therapy in culture-proven neonatal sepsis. Journal of Tropical Pediatrics2010;56(6):433-5. [DOI: 10.1093/tropej/fmq012] [PMID: 20185560]">Gathwala 2010</a>; <a href="./references#CD013836-bbs2-0028" title="HansenTN , RitterDA , SpeerME , KennyJD , RudolphAJ . A randomized, controlled study of oral gentamicin in the treatment of neonatal necrotizing enterocolitis. Journal of Pediatrics1980;97(5):836-39. [DOI: 10.1016/s0022-3476(80)80283-6] [PMID: 7000998]">Hansen 1980</a>; <a href="./references#CD013836-bbs2-0031" title="LanghendriesJP , BattistiO , BertrandJM , FrançoisA , DarimontJ , TulkensPM , et al. Once daily administration of amikacin. Adaptation to neonatology for infants less than 3 days of postnatal age [Administration en dose unique journalière de l'amikacine. Adaptation à la néonatologie pour des enfants traités avant le 3ème jour d'âge postnatal]. Médecine et Maladies Infectieuses1993;23(7):44-54. [DOI: 10.1016/S0399-077X(05)80984-9]">Langhendries 1993</a>; <a href="./references#CD013836-bbs2-0035" title="McCrackenGH , MizeSG . A controlled study of intrathecal antibiotic therapy in Gram-negative enteric meningitis of infancy. Report of the Neonatal Meningitis Cooperative Study Group. Journal of Pediatrics1976;89(1):66-72. [DOI: 10.1016/s0022-3476(76)80929-8] [PMID: 778366]">McCracken 1976</a>; <a href="./references#CD013836-bbs2-0039" title="MulubwaM , GrieselHA , MugaboP , DippenaarR , vanWykL . Assessment of vancomycin pharmacokinetics and dose regimen optimisation in preterm neonates. Drugs in Research &amp; Development2020;20(2):105-13. [DOI: 10.1007/s40268-020-00302-7] [PMID: 32266599]">Mulubwa 2020</a>; <a href="./references#CD013836-bbs2-0043" title="RohatgiS , DewanP , FaridiMM , KumarA , MalhotraRK , BatraP . Seven versus 10 days antibiotic therapy for culture-proven neonatal sepsis: a randomised controlled trial. Journal of Paediatrics and Child Health2017;53(6):556-62. [DOI: 10.1111/jpc.13518] [PMID: 28398692]">Rohatgi 2017</a>). </p> </li> <li> <p>Four trials included only early‐onset neonatal sepsis (<a href="./references#CD013836-bbs2-0027" title="HammerbergO , KurnitzkiC , WattsJ , RosenbloomD . Randomized trial using piperacillin versus ampicillin and amikacin for treatment of premature neonates with risk factors for sepsis. European Journal of Clinical Microbiology &amp; Infectious Diseases1989;8(3):241-4. [DOI: 10.1007/BF01965268] [PMID: 2496993]">Hammerberg 1989</a>; <a href="./references#CD013836-bbs2-0036" title="MetsvahtT , IlmojaML , ParmU , MaipuuL , MerilaM , LutsarI . Comparison of ampicillin plus gentamicin vs penicillin plus gentamicin in empiric treatment of neonates at risk of early onset sepsis. Acta Paediatrica, International Journal of Paediatrics2010;99(5):665-72. [DOI: 10.1111/j.1651-2227.2010.01687.x] [PMID: 20096030]MetsvahtT , IlmojaML , ParmU , MerilaM , MaipuuL , MuurseppP , et al. Ampicillin versus penicillin in the empiric therapy of extremely low-birthweight neonates at risk of early onset sepsis. Pediatrics International2011;53(6):873-80. [DOI: 10.1111/j.1442-200X.2011.03468.x] [PMID: 21895866]ParmU , MetsvahtT , SeppE , IlmojaML , PisarevH , PauskarM , et al. Impact of empiric antibiotic regimen on bowel colonization in neonates with suspected early onset sepsis. European Journal of Clinical Microbiology &amp; Infectious Diseases2010;29(7):807-16. [DOI: 10.1007/s10096-010-0931-1] [PMID: 20446013]">Metsvaht 2010</a>; <a href="./references#CD013836-bbs2-0044" title="SnellingS , HartCA , CookeRW . Ceftazidime or gentamicin plus benzylpenicillin in neonates less than forty-eight hours old. Journal of Antimicrobial Chemotherapy1983;12(Suppl A):353-6. [DOI: 10.1093/jac/12.suppl_a.353] [PMID: 6352643]">Snelling 1983</a>; <a href="./references#CD013836-bbs2-0048" title="TewariVV , JainN . Monotherapy with amikacin or piperacillin-tazobactum empirically in neonates at risk for early-onset sepsis: a randomized controlled trial. Journal of Tropical Pediatrics2014;60(4):297-302. [DOI: 10.1093/tropej/fmu017] [PMID: 24699298]">Tewari 2014</a>). </p> </li> <li> <p>One trial included adults (<a href="./references#CD013836-bbs2-0012" title="BassettiD , CrucianiM , SolbiatiM , RubiniF , GandolaL , ValentiG , et al. Comparative efficacy of ceftriaxone versus ceftazidime in the treatment of nosocomial lower respiratory tract infections. Chemotherapy1991;37(5):371-5. [DOI: 10.1159/000238881] [PMID: 1804598]">Bassetti 1991</a>). </p> </li> <li> <p>Two trials were not randomised (<a href="./references#CD013836-bbs2-0019" title="EbrahimGJ . Sepsis of the new-born (a therapeutic trial with gentamicin). East African Medical Journal1969;46(1):30-3. [PMID: 5770754]">Ebrahim 1969</a>; <a href="./references#CD013836-bbs2-0042" title="OralR , Akisü, M, KültürsayN , VardarF , TansuğN . Neonatal Klebsiella pneumonia sepsis and imipenem/cilastatin. Indian Journal of Pediatrics1998;65(1):121-9. [DOI: 10.1007/BF02849703] [PMID: 10771955]">Oral 1998</a>). </p> </li> <li> <p>Eleven trials did not include neonates with late‐onset sepsis (<a href="./references#CD013836-bbs2-0008" title="AlinejadS , YousefichaijanP , RezagholizamenjanyM , RafieY , KahbaziM , ArjmandA . Nephrotoxic effect of gentamicin and amikacin in neonates with Infection. Nephro-Urology Monthly2018;10(2):e58580. [DOI: 10.5812/numonthly.58580]">Alinejad 2018</a>; <a href="./references#CD013836-bbs2-0009" title="AronoffSC , ReedMD , O'BrienCA , BlumerJL . Comparison of the efficacy and safety of ceftriaxone to ampicillin/chloramphenicol in the treatment of childhood meningitis. Journal of Antimicrobial Chemotherapy1984;13(2):143-51. [DOI: 10.1093/jac/13.2.143] [PMID: 6323376]">Aronoff 1984</a>; <a href="./references#CD013836-bbs2-0014" title="ChartrandSA , MarksMI , ScribnerRK , JohnstonJT , FrederickDF . Moxalactam therapy of haemophilus influenzae type B meningitis in children. Journal of Pediatrics1984;104(3):454-9. [DOI: 10.1016/s0022-3476(84)81116-6] [PMID: 6608581]">Chartrand 1984</a>; <a href="./references#CD013836-bbs2-0016" title="CollinsMD , DajaniAS , KimKS , KingDR , KaplanSL , AzimiPH , et al. Comparison of ampicillin/sulbactam plus aminoglycoside vs. ampicillin plus clindamycin plus aminoglycoside in the treatment of intraabdominal infections in children. The Multicenter Group. Pediatric Infectious Disease Journal1998;17(3 Suppl):S15-8; discussion S20-1. [DOI: 10.1097/00006454-199803001-00005] [PMID: 9519910]">Collins 1998</a>; <a href="./references#CD013836-bbs2-0018" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 Suppl):S158-63. [DOI: 10.1097/01.inf.0000086955.93702.c7] [PMID: 14520141]">Deville 2003</a>; <a href="./references#CD013836-bbs2-0021" title="FeiginRD , StechenbergBW , ChangMJ , DunkleLM , WongML , PalkesH , et al. Prospective evaluation of treatment of Hemophilus influenzae meningitis. Journal of Pediatrics1976;88(4 Pt 1):542-8. ">Feigin 1976</a>; <a href="./references#CD013836-bbs2-0029" title="JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(9 Suppl):S164-71. [DOI: 10.1097/01.inf.0000086956.45566.55] [PMID: 14520142]">Jantausch 2003</a>; <a href="./references#CD013836-bbs2-0030" title="KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al, Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. [DOI: 10.1097/01.inf.0000078160.29072.42] [PMID: 12913766]">Kaplan 2003</a>; <a href="./references#CD013836-bbs2-0033" title="LönnerholmG , BengtssonS , EwaldU . Oral pivampicillin and amoxycillin in newborn infants. Scandinavian Journal of Infectious Diseases1982;14(2):127-30. [DOI: 10.3109/inf.1982.14.issue-2.10] [PMID: 7100823]">Lönnerholm 1982</a>; <a href="./references#CD013836-bbs2-0052" title="ViganòA , PrincipiN . A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients. Journal of Chemotherapy1995;7(Suppl 2):95-101. [PMID: 8622117]">Viganò 1995</a>; <a href="./references#CD013836-bbs2-0053" title="WellsTG , TrangJM , BrownAL , MarmerBC , JacobsRF . Cefotaxime therapy of bacterial meningitis in children. Journal of Antimicrobial Chemotherapy1984;14(Suppl B):181-9. [DOI: 10.1093/jac/14.suppl_b.181] [PMID: 6094438]">Wells 1984</a>). </p> </li> </ul> </p> <p>When the participant age was unclear or separate data were not available for late‐onset sepsis, we contacted the study authors. However, we obtained no additional information on these trials. </p> </section> </section> <section id="CD013836-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed all the included studies at overall high risk of bias (<a href="#CD013836-fig-0002">Figure 2</a>). We contacted the authors for clarification, as some data were missing and several bias domains were unclear. </p> <div class="figure" id="CD013836-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013836-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013836-sec-0059"> <h4 class="title">Allocation</h4> <p>Three trials used a computer program to generate the sequence resulting in assessment of low risk (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>; <a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>; <a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). Two trials did not describe how allocation sequence generation was performed resulting in assessment of unclear (<a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>; <a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>). </p> <p>Three trials allocated with concealment using serially numbered opaque sealed envelopes or had the randomisation list kept confidential and were at low risk of bias (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>; <a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>; <a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). Two trials did not describe allocation concealment and were at unclear risk of bias (<a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>; <a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>). </p> </section> <section id="CD013836-sec-0060"> <h4 class="title">Blinding</h4> <p>Two trials did not blind participants or treatment providers resulting in assessment of high risk of performance bias (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>; <a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>). Two trials did not describe methods of blinding (<a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>; <a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>), and one trial was only described as single‐blinded (without specifications) (<a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>), resulting in unclear risk of performance bias. </p> <p>Two trials did not blind outcome assessors resulting in assessment of high risk of detection bias (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>; <a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>). Three trials did not describe whether outcome assessors were blinded resulting in unclear risk of detection bias (<a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>; <a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>; <a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). </p> </section> <section id="CD013836-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>All trials used either intention‐to‐treat analysis or had no or few dropouts resulting in assessment of low risk of attrition bias. </p> </section> <section id="CD013836-sec-0062"> <h4 class="title">Selective reporting</h4> <p>All trials reported mortality resulting in assessment of low risk of reporting bias.</p> </section> <section id="CD013836-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>Review authors observed no other biases.</p> </section> </section> <section id="CD013836-sec-0064"> <h3 class="title" id="CD013836-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD013836-tbl-0001"><b>Summary of findings 1</b> Cefazolin plus amikacin compared with vancomycin plus amikacin for late‐onset neonatal sepsis</a>; <a href="./full#CD013836-tbl-0002"><b>Summary of findings 2</b> Ticarcillin plus clavulanic acid compared with flucloxacillin and gentamicin for late‐onset neonatal sepsis</a>; <a href="./full#CD013836-tbl-0003"><b>Summary of findings 3</b> Cloxacillin plus amikacin compared with cefotaxime plus gentamicin for neonatal late‐onset sepsis</a>; <a href="./full#CD013836-tbl-0004"><b>Summary of findings 4</b> Meropenem compared with standard care for neonatal late‐onset sepsis</a>; <a href="./full#CD013836-tbl-0005"><b>Summary of findings 5</b> Vancomycin plus gentamicin compared with vancomycin plus aztreonam for late‐onset neonatal sepsis</a> </p> <p>We included five trials (580 participants) that met all the inclusion criteria (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>; <a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>; <a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>; <a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>; <a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). We were able to assess in part all‐cause mortality, serious adverse events, circulatory support, nephrotoxicity, neurological developmental impairment, and NEC as primary and secondary outcomes. However, the five trials assessed comparisons with different antibiotic regimens. Hence, we performed no meta‐analyses, no TSA, and no subgroup analysis on any outcomes. We estimated the optimal information size for all of the outcomes and the optimal information size was not reached for any of the comparisons (<a href="./full#CD013836-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013836-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013836-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD013836-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD013836-tbl-0005">summary of findings Table 5</a>). </p> <section id="CD013836-sec-0065"> <h4 class="title">Cefazolin plus amikacin compared with vancomycin plus amikacin</h4> <p>We found one trial comparing cefazolin plus amikacin with vancomycin plus amikacin (<a href="./full#CD013836-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD013836-sec-0066"> <h5 class="title">Primary outcome</h5> <section id="CD013836-sec-0067"> <h6 class="title">All‐cause mortality</h6> <p>One trial randomising 109 participants comparing cefazolin plus amikacin with vancomycin plus amikacin showed no evidence of a difference in all‐cause mortality (RR 0.70, 95% CI 0.29 to 1.66; very low‐certainty evidence; <a href="./references#CD013836-fig-0003" title="">Analysis 1.1</a>) (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>). </p> </section> </section> <section id="CD013836-sec-0068"> <h5 class="title">Secondary outcomes</h5> <section id="CD013836-sec-0069"> <h6 class="title">Serious adverse events</h6> <p>One trial randomising 109 participants comparing cefazolin plus amikacin with vancomycin plus amikacin showed no evidence of a difference in serious adverse events (RR 0.70, 95% CI 0.29 to 1.66; very low‐certainty evidence; <a href="./references#CD013836-fig-0004" title="">Analysis 1.2</a>) (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>). </p> </section> <section id="CD013836-sec-0070"> <h6 class="title">Respiratory support</h6> <p>The trial did not report respiratory support.</p> </section> <section id="CD013836-sec-0071"> <h6 class="title">Circulatory support</h6> <p>The trial did not report circulatory support.</p> </section> <section id="CD013836-sec-0072"> <h6 class="title">Nephrotoxicity</h6> <p>The trial did not report nephrotoxicity.</p> </section> <section id="CD013836-sec-0073"> <h6 class="title">Neurological developmental impairment</h6> <p>The trial did not report neurological developmental impairment.</p> </section> <section id="CD013836-sec-0074"> <h6 class="title">Necrotising enterocolitis</h6> <p>The trial did not report NEC.</p> </section> <section id="CD013836-sec-0075"> <h6 class="title">Ototoxicity</h6> <p>The trial did not report ototoxicity.</p> </section> </section> </section> <section id="CD013836-sec-0076"> <h4 class="title">Ticarcillin plus clavulanic acid compared with flucloxacillin plus gentamicin</h4> <p>We found one trial comparing ticarcillin plus clavulanic acid with flucloxacillin plus gentamicin (<a href="./full#CD013836-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD013836-sec-0077"> <h5 class="title">Primary outcome</h5> <section id="CD013836-sec-0078"> <h6 class="title">All‐cause mortality</h6> <p>One trial randomising 28 participants comparing ticarcillin plus clavulanic acid with flucloxacillin plus gentamicin showed no evidence of a difference in all‐cause mortality (RR 0.20, 95% CI 0.01 to 3.82; very low‐certainty evidence; <a href="./references#CD013836-fig-0005" title="">Analysis 2.1</a>) (<a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>). </p> </section> </section> <section id="CD013836-sec-0079"> <h5 class="title">Secondary outcomes</h5> <section id="CD013836-sec-0080"> <h6 class="title">Serious adverse events</h6> <p>One trial randomising 28 participants comparing ticarcillin plus clavulanic acid with flucloxacillin plus gentamicin showed no evidence of a difference in serious adverse events (RR 0.20, 95% CI 0.01 to 3.82; <a href="./references#CD013836-fig-0006" title="">Analysis 2.2</a>; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>). </p> </section> <section id="CD013836-sec-0081"> <h6 class="title">Respiratory support</h6> <p>The trial did not report respiratory support.</p> </section> <section id="CD013836-sec-0082"> <h6 class="title">Circulatory support</h6> <p>The trial did not report circulatory support.</p> </section> <section id="CD013836-sec-0083"> <h6 class="title">Nephrotoxicity</h6> <p>The trial did not report nephrotoxicity.</p> </section> <section id="CD013836-sec-0084"> <h6 class="title">Neurological developmental impairment</h6> <p>The trial did not report neurological developmental impairment.</p> </section> <section id="CD013836-sec-0085"> <h6 class="title">Necrotising enterocolitis</h6> <p>The trial did not report NEC.</p> </section> <section id="CD013836-sec-0086"> <h6 class="title">Ototoxicity</h6> <p>The trial did not report ototoxicity.</p> </section> </section> </section> <section id="CD013836-sec-0087"> <h4 class="title">Cloxacillin plus amikacin compared with cefotaxime plus gentamicin</h4> <p>We found one study comparing cloxacillin plus amikacin with cefotaxime plus gentamicin (<a href="./full#CD013836-tbl-0003">summary of findings Table 3</a>). </p> <section id="CD013836-sec-0088"> <h5 class="title">Primary outcome</h5> <section id="CD013836-sec-0089"> <h6 class="title">All‐cause mortality</h6> <p>One trial randomising 90 participants comparing cloxacillin plus amikacin with cefotaxime plus gentamicin showed no evidence of a difference in all‐cause mortality (RR 0.38, 95% CI 0.11 to 1.27; very low‐certainty evidence; <a href="./references#CD013836-fig-0007" title="">Analysis 3.1</a>) (<a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). </p> </section> </section> <section id="CD013836-sec-0090"> <h5 class="title">Secondary outcomes</h5> <section id="CD013836-sec-0091"> <h6 class="title">Serious adverse events</h6> <p>One trial randomising 90 participants comparing cloxacillin plus amikacin with cefotaxime plus gentamicin showed no evidence of a difference in serious adverse events (RR 0.50, 95% CI 0.17 to 1.48; very low‐certainty evidence; <a href="./references#CD013836-fig-0008" title="">Analysis 3.2</a>) (<a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). </p> </section> <section id="CD013836-sec-0092"> <h6 class="title">Respiratory support</h6> <p>The trial did not report respiratory support.</p> </section> <section id="CD013836-sec-0093"> <h6 class="title">Circulatory support</h6> <p>One trial randomising 90 participants comparing cloxacillin plus amikacin with cefotaxime plus gentamicin showed no evidence of a difference in circulatory support (RR 0.50, 95% CI 0.17 to 1.48; very low‐certainty evidence; <a href="./references#CD013836-fig-0009" title="">Analysis 3.3</a>) (<a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). </p> </section> <section id="CD013836-sec-0094"> <h6 class="title">Nephrotoxicity</h6> <p>One trial randomising 90 participants comparing cloxacillin plus amikacin with cefotaxime plus gentamicin showed no evidence of a difference in nephrotoxicity (RR 0.25, 95% CI 0.03 to 2.05; very low‐certainty evidence; <a href="./references#CD013836-fig-0010" title="">Analysis 3.4</a>) (<a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). </p> </section> <section id="CD013836-sec-0095"> <h6 class="title">Neurological developmental impairment</h6> <p>The trial did not report neurological developmental impairment.</p> </section> <section id="CD013836-sec-0096"> <h6 class="title">Necrotising enterocolitis</h6> <p>The trial did not report NEC.</p> </section> <section id="CD013836-sec-0097"> <h6 class="title">Ototoxicity</h6> <p>The trial did not report ototoxicity.</p> </section> </section> </section> <section id="CD013836-sec-0098"> <h4 class="title">Meropenem compared with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin) </h4> <p>We found one trial comparing meropenem compared with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin) (<a href="./full#CD013836-tbl-0004">summary of findings Table 4</a>). </p> <section id="CD013836-sec-0099"> <h5 class="title">Primary outcome</h5> <section id="CD013836-sec-0100"> <h6 class="title">All‐cause mortality</h6> <p>One trial randomising 271 participants comparing meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin) showed no evidence of a difference in all‐cause mortality (RR 1.42, 95% CI 0.56 to 3.62; very low‐certainty evidence; <a href="./references#CD013836-fig-0011" title="">Analysis 4.1</a>) (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>). </p> </section> </section> <section id="CD013836-sec-0101"> <h5 class="title">Secondary outcomes</h5> <section id="CD013836-sec-0102"> <h6 class="title">Serious adverse events</h6> <p>One trial randomising 271 participants comparing meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin) showed no evidence of a difference in serious adverse events (RR 1.54, 95% CI 0.90 to 2.66; very low‐certainty evidence; <a href="./references#CD013836-fig-0012" title="">Analysis 4.2</a>) (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>). </p> </section> <section id="CD013836-sec-0103"> <h6 class="title">Respiratory support</h6> <p>The trial did not report respiratory support.</p> </section> <section id="CD013836-sec-0104"> <h6 class="title">Circulatory support</h6> <p>The trial did not report circulatory support.</p> </section> <section id="CD013836-sec-0105"> <h6 class="title">Nephrotoxicity</h6> <p>The trial did not report nephrotoxicity.</p> </section> <section id="CD013836-sec-0106"> <h6 class="title">Neurological developmental impairment</h6> <p>One trial randomising 271 participants comparing meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin) showed no evidence of a difference in neurological developmental impairment (RR 0.87, 95% CI 0.51 to 1.48; very low‐certainty evidence; <a href="./references#CD013836-fig-0013" title="">Analysis 4.3</a>) (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>). </p> </section> <section id="CD013836-sec-0107"> <h6 class="title">Necrotising enterocolitis</h6> <p>One trial randomising 271 participants comparing meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin) showed no evidence of a difference in NEC (RR 0.68, 95% CI 0.33 to 1.42; very low‐certainty evidence; <a href="./references#CD013836-fig-0014" title="">Analysis 4.4</a>) (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>). </p> </section> <section id="CD013836-sec-0108"> <h6 class="title">Ototoxicity</h6> <p>The trial did not report ototoxicity.</p> </section> </section> </section> <section id="CD013836-sec-0109"> <h4 class="title">Vancomycin plus gentamicin compared with vancomycin plus aztreonam</h4> <p>We found one trial comparing vancomycin plus gentamicin compared with vancomycin plus aztreonam (<a href="./full#CD013836-tbl-0005">summary of findings Table 5</a>). </p> <section id="CD013836-sec-0110"> <h5 class="title">Primary outcome</h5> <section id="CD013836-sec-0111"> <h6 class="title">All‐cause mortality</h6> <p>One trial randomising 81 participants comparing vancomycin plus gentamicin with vancomycin plus aztreonam showed no evidence of a difference in all‐cause mortality (RR 0.65, 95% CI 0.20 to 2.13; very low‐certainty evidence; <a href="./references#CD013836-fig-0015" title="">Analysis 5.1</a>) (<a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>). </p> </section> </section> <section id="CD013836-sec-0112"> <h5 class="title">Secondary outcomes</h5> <section id="CD013836-sec-0113"> <h6 class="title">Serious adverse events</h6> <p>One trial randomising 81 participants comparing vancomycin plus gentamicin with vancomycin plus aztreonam showed no evidence of a difference in serious adverse events (RR 0.65, 95% CI 0.20 to 2.13; very low‐certainty evidence; <a href="./references#CD013836-fig-0016" title="">Analysis 5.2</a>) (<a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>). </p> </section> <section id="CD013836-sec-0114"> <h6 class="title">Respiratory support</h6> <p>The trial did not report respiratory support.</p> </section> <section id="CD013836-sec-0115"> <h6 class="title">Circulatory support</h6> <p>The trial did not report circulatory support.</p> </section> <section id="CD013836-sec-0116"> <h6 class="title">Nephrotoxicity</h6> <p>The trial did not report nephrotoxicity.</p> </section> <section id="CD013836-sec-0117"> <h6 class="title">Neurological developmental impairment</h6> <p>The trial did not report neurological developmental impairment.</p> </section> <section id="CD013836-sec-0118"> <h6 class="title">Necrotising enterocolitis</h6> <p>One trial randomising 81 participants comparing vancomycin plus gentamicin with vancomycin plus aztreonam showed no evidence of a difference in NEC (RR 12.69, 95% CI 0.74 to 218.09; very low‐certainty evidence; <a href="./references#CD013836-fig-0017" title="">Analysis 5.3</a>) (<a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>). </p> </section> <section id="CD013836-sec-0119"> <h6 class="title">Ototoxicity</h6> <p>The trial did not report ototoxicity.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013836-sec-0120" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013836-sec-0120"></div> <section id="CD013836-sec-0121"> <h3 class="title" id="CD013836-sec-0121">Summary of main results</h3> <p>Evidence from five RCTs including 580 participants contributed data to our predefined outcomes. There is insufficient information to assess the relative effects of any of the antibiotics compared. Furthermore, these trials had high risk of bias. In summary, the certainty of the evidence was very low. </p> <p>We conducted no meta‐analyses due to a lack of relevant data. The optimal information size was not reached for any of the comparisons (<a href="./full#CD013836-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013836-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013836-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD013836-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD013836-tbl-0005">summary of findings Table 5</a>). </p> <p>When assessing all‐cause mortality: one trial randomising 109 participants showed no evidence of a difference when comparing cefazolin plus amikacin with vancomycin plus amikacin (RR 0.70, 95% CI 0.29 to 1.66; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>); one trial randomising 28 participants showed no evidence of a difference when comparing ticarcillin plus clavulanic acid with flucloxacillin plus gentamicin (RR 0.20, 95% CI 0.01 to 3.82; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>); one trial randomising 90 participants showed no evidence of a difference when comparing cloxacillin plus amikacin with cefotaxime plus gentamicin (RR 0.38, 95% CI 0.11 to 1.27; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>); one trial randomising 71 participants showed no evidence of a difference when comparing meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin) (RR 1.42, 95% CI 0.56 to 3.62; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>); one trial randomising 81 participants showed no evidence of a difference when comparing vancomycin plus gentamicin with vancomycin plus aztreonam (RR 0.65, 95% CI 0.20 to 2.13; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>). </p> <p>When assessing serious adverse events: one trial randomising 109 participants showed no evidence of a difference when comparing cefazolin plus amikacin with vancomycin plus amikacin (RR 0.70, 95% CI 0.29 to 1.66; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0001" title="Ceriani CernadasJM , Fernandez JonusasS , MarquezM , GarsdA , MarianiG . Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial. Archivos Argentinos de Pediatría2014;112(4):308-14. [DOI: 10.5546/aap.2014.308] [PMID: 24955900]">Ceriani 2014</a>); one trial randomising 28 participants showed no evidence of a difference when comparing ticarcillin plus clavulanic acid with flucloxacillin plus gentamicin (RR 0.20, 95% CI 0.01 to 3.82; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0003" title="Miall-AllenVM , WhitelawAG , DarrellJH . Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. British Journal of Clinical Practice1988;42(7):273-9. [PMID: 3075503]">Miall‐Allen 1988</a>); one trial randomising 90 participants showed no evidence of a difference when comparing cloxacillin plus amikacin with cefotaxime plus gentamicin (RR 0.50, 95% CI 0.17 to 1.48; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>); one trial randomising 271 participants showed no evidence of a difference when comparing meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin) (RR 1.54, 95% CI 0.90 to 2.66; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>); one trial randomising 81 participants showed no evidence of a difference when comparing vancomycin plus gentamicin with vancomycin plus aztreonam (RR 0.65, 95% CI 0.20 to 2.13; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>). </p> <p>None of the trials reported respiratory support.</p> <p>When assessing circulatory support, one trial randomising 90 participants showed no evidence of a difference when comparing cloxacillin plus amikacin with cefotaxime plus gentamicin (RR 0.50, 95% CI 0.17 to 1.48; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). </p> <p>When assessing nephrotoxicity, one trial randomising 90 participants showed no evidence of a difference when comparing cloxacillin plus amikacin with cefotaxime plus gentamicin (RR 0.25, 95% CI 0.03 to 2.05; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0005" title="RamasamyS , BiswalN , BethouA , MathaiB . Comparison of two empiric antibiotic regimen in late onset neonatal sepsis – a randomized controlled trial. Journal of Tropical Pediatrics2014;60(1):83-6. [DOI: 10.1093/tropej/fmt080] [PMID: 24064510]">Ramasamy 2014</a>). </p> <p>When assessing neurological developmental impairment, one trial randomising 271 participants showed no evidence of a difference when comparing meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin) (RR 0.87, 95% CI 0.51 to 1.48; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>). </p> <p>When assessing NEC: one trial randomising 271 participants showed no evidence of a difference when comparing meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin) (RR 0.68, 95% CI 0.33 to 1.42; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>); one trial randomising 81 participants showed no evidence of a difference when comparing vancomycin plus gentamicin with vancomycin plus aztreonam (RR 12.69, 95% CI 0.74 to 218.09; very low‐certainty evidence) (<a href="./references#CD013836-bbs2-0004" title="MillarMR , MacKayP , LeveneM , LangdaleV , MartinC . Enterobacteriaceae and neonatal necrotising enterocolitis. Archives of Disease in Childhood1992;67(1 Spec No):53-6. [DOI: 10.1136/adc.67.1_spec_no.53] [PMID: 1536588]">Millar 1992</a>). </p> <p>None of the trials reported ototoxicity.</p> <p>The benefits and harms of different antibiotic regimens remain unclear owing to the lack of well‐powered trials, and the high risk of systematic errors. </p> </section> <section id="CD013836-sec-0122"> <h3 class="title" id="CD013836-sec-0122">Overall completeness and applicability of evidence</h3> <p>We were unable to perform any meta‐analyses due to lack of relevant data and the identified trials were underpowered. Therefore, it was not possible to conclude whether one antibiotic regimen was superior to another in neonates with late‐onset sepsis. More and larger RCTs with low risk of bias are needed. </p> </section> <section id="CD013836-sec-0123"> <h3 class="title" id="CD013836-sec-0123">Quality of the evidence</h3> <section id="CD013836-sec-0124"> <h4 class="title">Heterogeneity</h4> <p>As no meta‐analysis was performed, we did not assess heterogeneity.</p> </section> <section id="CD013836-sec-0125"> <h4 class="title">Risk of systematic error ('bias')</h4> <p>We found no trials and no outcome results at low risk of bias.</p> <p>It was not possible to assess publication bias, as we were only able to include five studies. </p> </section> <section id="CD013836-sec-0126"> <h4 class="title">Risk of random error ('play of chance')</h4> <p>It was not possible to perform TSA, as we performed no meta‐analyses.</p> </section> <section id="CD013836-sec-0127"> <h4 class="title">GRADE</h4> <p>We assessed the certainty of the evidence for each outcome by using the GRADE approach (<a href="./full#CD013836-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013836-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013836-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD013836-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD013836-tbl-0005">summary of findings Table 5</a>). The GRADE assessment generally showed that the evidence was of very‐low certainty. </p> </section> </section> <section id="CD013836-sec-0128"> <h3 class="title" id="CD013836-sec-0128">Potential biases in the review process</h3> <p>The main limitation of this review was the low number of randomised participants and hence paucity of evidence for the use of different antibiotic regimens. Another limitation was that some trials did not distinguish between early‐onset and late‐onset neonatal sepsis, which resulted in a large number of potentially relevant trials that were excluded. We used the broadest possible definition of late‐onset sepsis and the broadest choice of possible antibiotic regimens. This could potentially have caused the inclusion of trials with very a heterogeneous population and many different interventions. Despite this broad approach, we only found five trials. </p> <p>If that had been the case, we would have considered whether meta‐analysis could be justified. </p> <p>As indicated in our <a href="#CD013836-sec-0009">Background</a> section, there might be substantial differences between the pathogens across countries. The optimal antibiotic regimen might, therefore, vary according to country and local risks of antibiotic resistance. We did not include enough trials to confirm that this was the case. </p> <p>Despite the anticipated differences between antibiotic resistance at different sites, there could still be important differences between antibiotic regimens on clinical outcomes that would lead to generalised recommendations (<a href="./references#CD013836-bbs2-0143" title="PaulM , ShaniV , MuchtarE , KarivG , RobenshtokE , LeiboviciL . Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrobial Agents and Chemotherapy2010;54(11):4851-63. [DOI: 10.1128/AAC.00627-10] [PMID: 20733044]">Paul 2010</a>). </p> <p>For future updates, we will systematically assess the clinical heterogeneity (<a href="./references#CD013836-bbs2-0058" title="BarbateskovicM , KosterTM , EckRJ , MaagaardM , AfshariA , BlokzijlF , et al. A new tool to assess clinical diversity in meta-analyses (CDIM) of interventions. Journal of Clinical Epidemiology2021;135:29-41. [DOI: 10.1016/j.jclinepi.2021.01.023]">Barbateskovic 2021</a>). </p> </section> <section id="CD013836-sec-0129"> <h3 class="title" id="CD013836-sec-0129">Agreements and disagreements with other studies or reviews</h3> <p>The additional trials included in this version did not change the overall conclusions and recommendations of the former review (<a href="./references#CD013836-bbs2-0093" title="GordonA , JefferyHE . Antibiotic regimens for suspected late onset sepsis in newborn infants. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD004501. [DOI: 10.1002/14651858.CD004501.pub2]">Gordon 2005</a>). The largest included trial only randomised 271 participants and compared meropenem with standard care (<a href="./references#CD013836-bbs2-0002" title="LutsarI , ChazallonC , TrafojerU , VincentMC , CinziaA , ChiaraB , et al, NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. Plos One2020;15(3):e0229380. [DOI: 10.1371/journal.pone.0229380] [PMID: 32130261]">Lutsar 2020</a>). The authors found no evidence to suggest that meropenem was superior to standard care. Although the largest of our included trials, this sample size is presumably underpowered to detect any evidence of a difference between two antibiotic regimens on clinically important outcomes such as mortality and serious adverse events. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013836-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013836-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013836-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cefazolin plus amikacin versus vancomycin plus amikacin, Outcome 1: All‐cause mortality" data-id="CD013836-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Cefazolin plus amikacin versus vancomycin plus amikacin, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cefazolin plus amikacin versus vancomycin plus amikacin, Outcome 2: Serious adverse events" data-id="CD013836-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Cefazolin plus amikacin versus vancomycin plus amikacin, Outcome 2: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ticarcillin plus clavulanic acid versus flucloxacillin plus gentamicin, Outcome 1: All‐cause mortality" data-id="CD013836-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Ticarcillin plus clavulanic acid versus flucloxacillin plus gentamicin, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ticarcillin plus clavulanic acid versus flucloxacillin plus gentamicin, Outcome 2: Serious adverse events" data-id="CD013836-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Ticarcillin plus clavulanic acid versus flucloxacillin plus gentamicin, Outcome 2: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Cloxacillin plus amikacin versus cefotaxime plus gentamicin, Outcome 1: All‐cause mortality" data-id="CD013836-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Cloxacillin plus amikacin versus cefotaxime plus gentamicin, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Cloxacillin plus amikacin versus cefotaxime plus gentamicin, Outcome 2: Serious adverse events" data-id="CD013836-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Cloxacillin plus amikacin versus cefotaxime plus gentamicin, Outcome 2: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Cloxacillin plus amikacin versus cefotaxime plus gentamicin, Outcome 3: Circulatory support" data-id="CD013836-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Cloxacillin plus amikacin versus cefotaxime plus gentamicin, Outcome 3: Circulatory support </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Cloxacillin plus amikacin versus cefotaxime plus gentamicin, Outcome 4: Nephrotoxicity" data-id="CD013836-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Cloxacillin plus amikacin versus cefotaxime plus gentamicin, Outcome 4: Nephrotoxicity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Meropenem versus standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin), Outcome 1: All‐cause mortality" data-id="CD013836-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Meropenem versus standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin), Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Meropenem versus standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin), Outcome 2: Serious adverse events" data-id="CD013836-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Meropenem versus standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin), Outcome 2: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Meropenem versus standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin), Outcome 3: Neurological developmental impairment" data-id="CD013836-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Meropenem versus standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin), Outcome 3: Neurological developmental impairment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Meropenem versus standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin), Outcome 4: Necrotising enterocolitis" data-id="CD013836-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Meropenem versus standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin), Outcome 4: Necrotising enterocolitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Vancomycin plus gentamicin versus vancomycin plus aztreonam, Outcome 1: All‐cause mortality" data-id="CD013836-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Vancomycin plus gentamicin versus vancomycin plus aztreonam, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Vancomycin plus gentamicin versus vancomycin plus aztreonam, Outcome 2: Serious adverse events" data-id="CD013836-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Vancomycin plus gentamicin versus vancomycin plus aztreonam, Outcome 2: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013836-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/urn:x-wiley:14651858:media:CD013836:CD013836-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Vancomycin plus gentamicin versus vancomycin plus aztreonam, Outcome 3: Necrotising enterocolitis" data-id="CD013836-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_t/tCD013836-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Vancomycin plus gentamicin versus vancomycin plus aztreonam, Outcome 3: Necrotising enterocolitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/media/CDSR/CD013836/image_n/nCD013836-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013836-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cefazolin plus amikacin compared with vancomycin plus amikacin for late‐onset neonatal sepsis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cefazolin + amikacin compared with vancomycin + amikacin for late‐onset neonatal sepsis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborns with late‐onset sepsis </p> <p><b>Settings:</b> neonatal intensive care unit in Argentina </p> <p><b>Intervention:</b> cefazolin + amikacin </p> <p><b>Comparison:</b> vancomycin + amikacin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Vancomycin + amikacin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cefazolin + amikacin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000<br/>(39 to 223) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b> </p> <p>(0.29 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 3022 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000<br/>(39 to 223) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b> </p> <p>(0.29 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 3022 (RR 0.80, α 0.05, β 0.20)</p> <p>Serious adverse events were deaths.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of very serious risk of bias, very serious imprecision of results, and serious risk of indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cefazolin plus amikacin compared with vancomycin plus amikacin for late‐onset neonatal sepsis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013836-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ticarcillin plus clavulanic acid compared with flucloxacillin and gentamicin for late‐onset neonatal sepsis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ticarcillin + clavulanic acid compared with flucloxacillin + gentamicin for late‐onset neonatal sepsis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborns with late‐onset sepsis </p> <p><b>Settings:</b> neonatal intensive care unit in England </p> <p><b>Intervention:</b> ticarcillin + clavulanic acid </p> <p><b>Comparison:</b> flucloxacillin + gentamicin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Flucloxacillin + gentamicin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Ticarcillin + clavulanic acid</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/>(1 to 546) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.20</b> </p> <p>(0.01 to 3.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 4306 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/>(1 to 546) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.20</b> </p> <p>(0.01 to 3.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 4306 (RR 0.80, α 0.05, β 0.20)</p> <p>Serious adverse events were deaths.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of very serious risk of bias, very serious imprecision of results, and serious risk of indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ticarcillin plus clavulanic acid compared with flucloxacillin and gentamicin for late‐onset neonatal sepsis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013836-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Cloxacillin plus amikacin compared with cefotaxime plus gentamicin for neonatal late‐onset sepsis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cloxacillin + amikacin compared with cefotaxime + gentamicin for neonatal late‐onset sepsis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborns with late‐onset sepsis </p> <p><b>Settings:</b> neonatal intensive care unit in India </p> <p><b>Intervention:</b> cloxacillin + amikacin </p> <p><b>Comparison:</b> cefotaxime + gentamicin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cefotaxime + gentamicin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cloxacillin + amikacin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000<br/>(22 to 254) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.38</b> </p> <p>(0.11 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 2894 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000<br/>(34 to 296) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> </p> <p>(0.17 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 2894 (RR 0.80, α 0.05, β 0.20)</p> <p>Serious adverse events were participants who developed shock.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Circulatory support</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000<br/>(34 to 296) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> </p> <p>(0.17 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 2894 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nephrotoxicity</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/>(3 to 205) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.25</b> </p> <p>(0.03 to 2.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 6428 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of very serious risk of bias, very serious imprecision of results, and serious risk of indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Cloxacillin plus amikacin compared with cefotaxime plus gentamicin for neonatal late‐onset sepsis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013836-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Meropenem compared with standard care for neonatal late‐onset sepsis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Meropenem compared with standard care for neonatal late‐onset sepsis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborns with late‐onset sepsis </p> <p><b>Settings:</b> neonatal intensive care units in Europe </p> <p><b>Intervention:</b> meropenem </p> <p><b>Comparison:</b> standard care (ampicillin + gentamicin or cefotaxime + gentamicin) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Meropenem</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Standard care</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/>(29 to 188) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.42</b> </p> <p>(0.56 to 3.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup> </p> <p><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 12976 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 1000<br/>(120 to 355) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.54</b> </p> <p>(0.90 to 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 4662 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurological developmental impairment</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>178 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155 per 1000<br/>(91 to 263) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> </p> <p>(0.51 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 3336 (RR 0.80, α 0.05, β 0.20)</p> <p>This outcome was number of participants with intracranial bleeding.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Necrotising enterocolitis</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/>(39 to 168) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.68</b> </p> <p>(0.33 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 5324 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CIS:</b> optimal information size; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of very serious risk of bias, very serious imprecision of results, and serious risk of indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Meropenem compared with standard care for neonatal late‐onset sepsis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013836-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Vancomycin plus gentamicin compared with vancomycin plus aztreonam for late‐onset neonatal sepsis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vancomycin + gentamicin compared with vancomycin + aztreonam for late‐onset neonatal sepsis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborns with late‐onset sepsis </p> <p><b>Settings:</b> neonatal intensive care units in England </p> <p><b>Intervention:</b> vancomycin + gentamicin </p> <p><b>Comparison:</b> vancomycin + aztreonam </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Vancomycin + aztreonam</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Vancomycin + gentamicin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000<br/>(30 to 320) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b> </p> <p>(0.20 to 2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 4072 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000<br/>(30 to 320) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b> </p> <p>(0.20 to 2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 4072 (RR 0.80, α 0.05, β 0.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Necrotising enterocolitis</b> </p> <p>maximum follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 12.69</b> </p> <p>(0.74 to 218.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: NA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NA:</b> not available; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of very serious risk of bias, very serious imprecision of results, and serious risk of indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Vancomycin plus gentamicin compared with vancomycin plus aztreonam for late‐onset neonatal sepsis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013836-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Commonly used clinical and laboratory criteria of sepsis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Clinical criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Laboratory criteria</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013836-list-0001"> <li> <p>Abdominal distension</p> </li> <li> <p>Skin and subcutaneous lesions such as petechial rash, abscesses, sclerema</p> </li> <li> <p>Cardiovascular signs (tachycardia/bradycardia, hypotension, poor perfusion)</p> </li> <li> <p>Respiratory signs (apnoea, cyanosis, tachypnoea, need for ventilator, increased oxygen requirement) </p> </li> <li> <p>Abnormal temperature (fever or hypothermia)</p> </li> <li> <p>Central nervous system signs (lethargy, hypotonia, seizure)</p> </li> <li> <p>Feeding problems</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013836-list-0002"> <li> <p>WBC</p> </li> <li> <p>Immature WBC:total WBC ratio</p> </li> <li> <p>Platelet count</p> </li> <li> <p>C‐reactive protein</p> </li> <li> <p>Metabolic acidosis</p> </li> <li> <p>Neutropenia</p> </li> <li> <p>Abnormal fibrinogen</p> </li> <li> <p>Hyperglycaemia and hypoglycaemia</p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>WBC: white blood cell.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Commonly used clinical and laboratory criteria of sepsis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/full#CD013836-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013836-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cefazolin plus amikacin versus vancomycin plus amikacin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.29, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.29, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cefazolin plus amikacin versus vancomycin plus amikacin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013836-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ticarcillin plus clavulanic acid versus flucloxacillin plus gentamicin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ticarcillin plus clavulanic acid versus flucloxacillin plus gentamicin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013836-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Cloxacillin plus amikacin versus cefotaxime plus gentamicin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.11, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.17, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Circulatory support <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.17, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Nephrotoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Cloxacillin plus amikacin versus cefotaxime plus gentamicin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013836-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Meropenem versus standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.56, 3.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.90, 2.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Neurological developmental impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.51, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.33, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Meropenem versus standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013836-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Vancomycin plus gentamicin versus vancomycin plus aztreonam</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.20, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.20, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.69 [0.74, 218.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Vancomycin plus gentamicin versus vancomycin plus aztreonam</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013836.pub2/references#CD013836-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013836.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013836-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013836-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013836-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD013836-note-0012">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013836-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013836-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013836-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013836-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013836\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013836\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013836\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013836\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013836\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013836.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013836.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013836.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013836.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013836.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717067359"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013836.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717067363"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013836.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918daedd7fd2936e',t:'MTc0MDcxNzA2Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 